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General Introduction 
Rationale and Hypothesis 
Hemolytic Uremic Syndrome (HUS) is a potentially lethal complication of hemorrhagic 
colitis (HC), an enteric infection caused by Enterohemorrhagic Esc&erzcAwz co# (EHEC) [1-
4]. HUS is the leading cause of acute renal failure in children in the United States and other 
industrialized countries [5,6], and is characterized by the triad of thrombocytopenia, 
microangiopathic hemolytic anemia, and acute renal failure [7]. The hemolysis in HUS is 
severe, often resulting in a packed cell volume that falls below 30%. Platelet counts can drop 
to 150,000 or less, and many patients require dialysis for the acute renal failure. HUS is 
caused by Shiga toxin 1 (Stxl) and Shiga toxin 2 (Stx2), which are produced by EHEC 
bacteria. Histologic lesions of HUS include endothelial cell necrosis and fibrin thrombi in 
the blood vessels of the renal cortex, the ileum and large intestine, and in some cases the 
brain of the affected individuals. Children, especially those under 5 years of age, and the 
elderly are more susceptible to HUS than adults [8, 9]. 
EHEC infections are common in the United States and throughout the developed and 
developing countries of the world. In the United States, it is estimated that 70,000 cases of 
EHEC infection occur annually. EHEC infections may be asymptomatic, or may present as 
moderate to severe bloody or non-bloody diarrhea. HUS develops in up to 10% of children 
infected with EHEC, and is fatal in up to 5 to 35% of cases [7-9]. The most common EHEC 
in the United States is & co# 0157:H7, accounting for approximately 80% of cases. This 
strain is prevalent in ruminants, and is thought by some to be adapted to cattle, where it 
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colonizes the ileum and large intestine, and has recently been found to persist at the ano­
rectal junction. E. co# 0157:H7, like other EHEC, forms closely adherent, intimate 
attachments to intestinal mucosal cells that are known as attaching and effacing (A/E) 
lesions. Up to 75% of cattle herds in the United States are thought to be infected with & coZ; 
0157:H7, although estimates of individual animal infection within these herds range from 3 
to 28%. Infections in cattle and other ruminants are more common in the spring and summer, 
which correlates with the highest incidence of hemorrhagic colitis and HUS in humans. 
Clinically, it is difficult to determine whether or not an individual with HC will develop 
HUS, and there are currently no effective treatments for HUS. 
Although it is known that HUS is caused by Stx, the mechanism of movement of Stx from 
the intestinal lumen, where it is produced, to the systemic circulation, where it causes the 
potentially fatal lesions of HUS, is poorly understood. Stx, like endotoxin and many other 
bacterial toxins, is not readily absorbed by the intestinal mucosa under normal circumstances. 
Although in vitro studies have shown that Stx I translocates across polarized intestinal 
epithelial cells by a transcellular pathway, and that Stx II translocates across polarized 
epithelial cells by a paracellular pathway, the dynamics and movement of Stx in vivo is 
poorly understood [10]. It is possible that the A/E lesions formed by most EHEC bacteria 
allow passage of the toxin into the altered mucosal cells, or that movement of the toxin is 
transcellular in vivo. Alternatively, it is possible that the host inflammatory response induces 
changes in mucosal permeability that allows Stx to move from the intestinal lumen to the 
systemic circulation. 
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It is our hypothesis that the host inflammatory response to EHEC induces HC and allows or 
enhances movement of Stx from the intestinal lumen to the systemic circulation. If this 
hypothesis is correct, it may be possible to design effective therapeutic intervention strategies 
based on regulating the host inflammatory response to EHEC. 
The objective of the first study in this dissertation was to develop a model of EHEC infection 
that would allow testing of the hypothesis that the host inflammatory response enhances 
movement of Stx from the intestinal lumen to the systemic circulation in EHEC infections. 
Although there are numerous animal models of EHEC infection, including the pig, most are 
used to study systemic effects of Stx or colonization factors associated with EHEC rather 
than mucosal permeability to Stx. Prior to work in this dissertation, previous pig models 
have used newborn (<24 hour old) pigs. However, newborn pigs acquire immunoglobulins 
and other macromolecules by passive transfer during the first 48 hours of life, making the 
newborn pig model inappropriate for studies of the mechanisms of Stx translocation. In 
order to circumvent this problem, a model of 3-day-old pig infection with EHEC 0157:H7 
was developed. 
The objective of the second study was to induce an inflammatory response in the cecum and 
large intestine of the 3-day-old pig, sites of intestinal colonization, and to determine the 
effects of the inflammatory response on mucosal permeability to Stx in this model. In the 
first study, the 3-day-old pigs were colonized by EHEC 0157:H7 and developed classic A/E 
lesions, but lacked or had only a very mild histologically detectable inflammatory response to 
infection. 
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The objective of the third study was to compare the clinical and systemic effects of EHEC 
infection and Stx absorption in 3-day-old pigs with and without colonic inflammation. This 
would allow determination of whether the host inflammatory response does or does not 
enhance Stx absorption. 
Dissertation Organization 
This dissertation consists of a general introduction and literature review (Chapter 1), 
followed by three manuscripts that have been prepared for submission to peer reviewed 
scientific journals (Chapters 2-4), and a general conclusion (Chapter 5). References are cited 
at the end of each chapter. 
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Introduction 
Enterohemorrhagic EscAerzc&wz co/z (EHEC) species, notably & co/z 0157:H7, are 
pathogens that cause a wide range of clinical syndromes in people, ranging from 
asymptomatic carriers, to non-bloody diarrhea, to bloody diarrhea, with or without systemic 
complications such as Hemolytic Uremic Syndrome (HUS), Thrombotic Thrombocytopenic 
Purpura (TIT), and death [1-4]. EHECs gained notoriety following an outbreak of 
hemorrhagic colitis (HC) and HUS associated with a fast food restaurant in the Pacific 
Northwest. The main cause of concern with EHECs is their ability to induce systemic 
disease, namely HUS [3, 5]. This review presents and discusses findings of EHEC studies, 
with emphasis on the host inflammatory response to EHEC and that response's possible 
effects on intestinal mucosal permeability to Shiga toxins (Stx). 
HUS 
Genera/ /nfbrmaf/on 
HUS, and the related condition TTP, are disease syndromes known as thrombotic 
microangiopathies (TMA). The majority of HUS cases (90% in the U.S.) are secondary to 
EHEC infections [6, 7]. HUS is the leading cause of acute renal failure in children in the 
U.S. and the industrialized world [8, 9]. HUS is characterized by thrombocytopenia, 
microangiopathic hemolytic anemia, and acute renal failure [10]. Approximately 10% of 
EHEC infections will proceed to HUS [11] and the majority of HUS cases occur in either the 
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very young or the very old [12]. HUS is caused by Shiga toxins (Stx) produced by EHEC. 
Stx 2 is primarily responsible for HUS [13]. Although Stx 1 is toxic to human glomerular 
endothelial cells (HGEC) m vffro it is not generally associated with HUS [14]. 
Sh/ga fox/ns 
The Shiga toxins are a group of structurally similar but antigenically distinct toxins that are 
formed by EHEC, and are composed of a single A unit and Ave B subunits [15]. Stx 1 is 
differs by only a single amino acid from the toxin produce by dysenfenae, from 
which the name was derived [16]. Stx 2 shares 56% amino acid homology with Stx I [6]. 
The alpha unit of Stx 1 and H is the functional toxin and works by irreversibly cleaving a 
specific adenine residue on the ribosomal RNA that encodes the 28s subunit [17]. This halts 
protein production in the target cell and rapidly leads to cell death, or sublethal cell injury. 
Stx binding 
The B subunits of the toxin bind to receptors on the target cell, and confer target specificity 
[18]. Stx 1 and 2 bind to the globotriacylceramide (Gb3) receptors, while the edema disease 
toxin, Stx 2e binds to globotetracylceramide (Gb4) receptors [18]. Binding to target cells is 
dependent not only on receptor density, but also upon the fatty acid composition of the Gb3 
receptor. Kiarash et al. reported that increased fatty acid chain length and unsaturated fatty 
acid chains improved Stx binding, and concluded that several overlapping moieties were 
recognized by the Stx B subunit, and that these moieties are differentially available based 
upon the fatty acid composition of the Gb3 receptor [19]. The Gb3/Gb4 receptors are 
differentially expressed in different tissues at a constitutive level [20], and can be up-
regulated by TNF alpha, butyrate, IL-8, and other substances [20-22]. Gb3 receptor 
expression in human glomerular endothelial cells (HGEC) is 1000 x higher than in human 
umbilical vein endothelium, which likely contributes to the exquisite sensitivity of HGEC to 
Stx, and makes the kidney a primary target of Stx In HUS [23]. 
Once bound to the target cell, Stx Is taken into the cell by endocytosis where it moves in a 
retrograde direction through the Golgi [24]. As previously mentioned, the A subunit acts by 
enzymatically depurinating a residue of the 28s rRNA, shutting down protein synthesis and 
killing or sublethally injuring the target cell. 
Symptoms of Hl/S 
Symptoms of HUS are related to the killing or sublethal injury of the target cells and the 
cascade of events that this induces. There are several cell types that are preferentially 
targeted by Stx due to their Gb3 expression, including glomerular endothelial cells, renal 
tubular cells, intestinal epithelial cells, and central nervous system endothelial cells [20,23, 
25, 26]. When endothelial cells in the glomeruli and other locations are damaged, they 
respond by releasing vonWillebrands factor (vWF), a potent pro-coagulant factor that 
contributes to hemostasia. Large multimers of vWF released from lethally or sublethally 
injured endothelial cells attract and activate platelets, which subsequently degranulate and 
start to form microthrombi in affected vessels. If the endothelial damage is sufficiently wide­
spread, this microthrombus formation leads to consumptive thrombocytopenia, which is one 
of the hallmarks ofHUS [27,28]. Microthrombi in small vessels cause turbulent blood flow, 
which has a shearing effect on red blood cells, and is believed to contribute to the hemolysis 
and red blood cell fragmentation seen in HUS [28]. Additionally, peroxidation of the lipid 
membranes of red blood cells can lead to increased fragility. Turi et al., reported increased 
lipid peroxidation by measuring malonyl dialdehyde levels in blood samples from HUS 
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patients, accompanied by increased oxidized glutathione levels and increased red blood cell 
fragility [29]. 
Uremia in HUS is caused primarily by decreased glomerular filtration, secondary to 
microthrombi within the renal arterioles and glomerular capillaries [30]. Toxin has been 
shown to be bound to renal tubular cells in human cases of HUS, and the direct toxic effect 
of Stx on tubular epithelial cells may also contribute to renal dysfunction seen in this disease 
[30]. 30-50% of HUS cases in humans also develop neurologic disease [31], which is 
believed to be secondary to Stx Induced endothelial damage with microthrombosis of 
arterioles within the brain, leading to small, multifocal areas of ischemic neuropathy [32-34]. 
Acute death occurs in 3-5% of HUS cases [7, 9]. Chronic renal sequelae can also occur, and 
include chronic proteinuria, and chronic renal insufficiency. There is progression to end-
stage kidney disease in 3-5% of cases [7]. Most deaths that occur in HUS are due to brain 
injury rather than renal injury [35]. 
EHEC-induced HUS generally develops around 6 days after the onset of EHEC symptoms 
(bloody or non-bloody diarrhea, cramping, etc.)[6]. There are several known risk factors for 
developing HUS, including increased urinary IL-6 levels, increased serum TNF and IL-8 
levels, high peripheral white blood cell count, and, as previously noted, extremes in age [9, 
30, 36-38]. The increased urinary IL-6 levels, increased serum TNF and IL-8 levels, and 
high peripheral WBC counts may be due to a heavier bacterial load or more severe infection, 
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or they may reveal a more robust host response to a bacterial infection than one that is only 
average in severity. 
Treatments 
Currently, there is no effective treatment for HUS beyond supportive care. Several studies 
suggest that antibiotics may be an additional risk factor for developing HUS, which may be 
due to the fact that Stx Is not released from the periplasmic space of the bacteria until 
bacteriolysis. However, other studies have shown that there is no effect, either positive or 
negative of antibiotic use in HC, and at least one study showed that antibiotic treatment with 
Fosfbmycin had a beneficial effect of decreasing the likelihood of HUS [27]. Additionally, 
anti-diarrheal medications have been shown to be a risk factor, presumably due to increased 
retention of feces that contains Stx [39,40]. Interestingly, Comick et al., recently showed 
that there is discordance between fecal Stx and HUS development in children. That is, high 
fecal Stx levels are not always associated with the development of HUS in children [41]. 
Although no effective treatments besides supportive care have been identified for HUS, there 
are several treatment strategies that have been tested, are currently being tested, or that have 
been proposed for the treatment of HUS. These treatments include toxin binding agents that 
may decrease or prevent Stx absorption [42], and hyper-immune globulin [27]. Binding 
agents are typically highly branched, non-absorbed molecules that bind Stx and keep it in the 
intestinal lumen until it is eliminated from the body. A somewhat different spin on the 
binding agents is the use of recombinant bacterium as a probiotic that expresses an Stx 
receptor mimic, and in one study protected mice from an otherwise 100% lethal challenge 
dose of STEC [43,44]. Unfortunately, clinical trials, to date, have been somewhat 
disappointing. Hyper-immune globulin is given in an attempt to bind or deactivate Stx that 
has already been absorbed into the body and prevent it from reaching sensitive cell 
populations. In pigs, Dean-Nystrom et al., have shown that vaccination of sows with intimin 
produces antibodies that are protective to suckling piglets [45]. Similarly, Mukheijee et al., 
showed that human monoclonal antibodies to Stx 2 protected mice and gnotobiotic piglets 
from disease following experimental challenge with EHEC strain 86-24 [46]. 
In studies preceding the ones presented in this thesis, colostrum deprived dairy calves 
infected with & co/z 0157:H7 and treated with an agent that inhibits neutrophil recruitment 
by blocking selectins, TBC 1269, had less severe clinical signs of E. co/z infection. Although 
it was later shown that cattle lack vascular receptors for Stx [47], if the hypothesis that the 
host inflammatory response enhances Stx translocation is correct, anti-inflammatory agents 
could play a role in treatment of HC and HUS. 
EHEC 
/nfroducf/on 
& co/z is an ubiquitous organism that colonizes the large intestinal tract of animals that range 
from invertebrates to humans. Most E. co/z are non-pathogenic, however, there are numerous 
strains of & co/z that produce a relatively wide variety of diseases. & co/z are classified by 
antigenic differences in the LPS (O antigen), flagellar (H antigen), or capsular (K antigen), if 
present [48]. By this system, different serotypes of & co/z are recognized. For example, E. 
co/z 0157:H7 is a strain of E. co/z that reacts the O (LPS) antigen number 157, and H 
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(flagellar) antigen number 7. & co/z are also classified based upon their pathogenic 
characteristics, or virulence factors (virotype). By this system, pathogenic & co/z are 
classified as Enteropathogenic & co/z (EPEC), Enterohemorrhagic & coZz (EHEC), 
Enteroinvasive & co/z (EIEC), Enterotoxigenic E. co/z (ETEC), and Shiga toxigenic E. co/z 
(STEC) [48]. The classifications can be overlapping, for example, some STEC are also 
EHEC. 
Mfru/ence factors 
The EHEC are a group of E. co/z, including & co/z 0157:H7, that contain the virulence 
factors Stx 1, Stx 2, or both. These bacteria have been recognized as a cause ofHUS since 
the early 1980's [27]. The EHECs that are most commonly responsible for HUS have a 
number of virulence factors, including a chromosomal pathogenicity island named the locus 
of enterocyte effacement (LEE) that contains the genes required for the attaching and 
effacing (A/E) phenotype, and a lysogenic bacteriophage that contains the gene sequences 
and operon control sequences for producing Stx's [49]. 
LEE 
The LEE is located on the bacterial chromosome and contains the genes for the so-called "E. 
co/z Secreted Proteins", or Esp's, intimin, and Tir, which are responsible for the intimate 
binding seen in A/E bacterial lesions, and a type III secretion apparatus encoded by the sen 
genes [50-52]. 
A/E Lesion formation 
Initial, loose, attachment of EHEC is incompletely understood, but is thought to be due to 
non-specific binding interactions between the bacteria and enterocytes. EPECs, which are 
similar to EHECs in that they form A/E lesions, form a pilus structure called a "bundle 
forming pilus" that is thought to participate in early binding activity, however, this pilus is 
not formed by EHEC [53]. The initial loose attachment of EHEC is followed by A/E lesion 
formation, which is dependent on eae and other genes encoded by the LEE [54-58], and is 
controlled by quorum sensing and other mechanisms [59]. Quorum sensing is a form of 
bacterial communication in which a reporter molecule, usually an acyl homoserine lactone-
signaling molecule, is produced by bacteria and released into the environment [60]. When 
the reporter molecule in the environment reaches a certain concentration, it induces a 
metabolic change or protein production in the bacteria. Quorum sensing in E. co/z uses the 
luxS gene [61]. When the population density of E. co/z 0157:H7 reaches a certain point, as 
reported by quorum sensing, the LEE is activated [59]. Presumably the first genes expressed 
are the seg and esg genes that encode the type HI secretion system. Type III secretion 
systems are characterized by a filamentous structure that extends through the inner and outer 
bacterial membranes. This filamentous structure, along with the secreted Esp proteins, forms 
a large syringe-like structure that is used to inject proteins notably Tir [56], into the 
host/target cell [51]. Once Tir is in place within the host cell membrane, it binds to intimin, 
the product of the eae gene. The host cell responds by rearranging actin filaments 
surrounding the bacteria to form small pedestal-like structures that are characteristic of A/E 
attachment [62]. This rearrangement of actin fibers is thought to be at least partially 
controlled by EspB [51]. Thus, the bacteria actually inserts it's own receptor into the host 
cell in order to accommodate it's attachment to enterocytes [56]. 
Stx production 
Control of Stx production, and the genes required for Stx production are located on a lambda 
bacteriophage, unlike the Stx gene in STzzgW/a (fysenferzae, which is located on the bacterial 
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chromosome [63]. Stx production is regulated m vivo by the iron concentration in bacterial 
environment. This is done by an upstream functional promotor that is regulated by the 
transcriptional repressor, Fur, which is iron-dependent [64]. Experimentally, Stx production 
can also be increased by phage regulators, but this is probably not significant z/i vivo [64]. 
Stx translocation 
vzfro studies have shown that Stx 1 and Stx 2 translocate across intestinal epithelial cell 
monolayers by different mechanisms [65]. Stx 1 translocation is saturable, requires energy, 
and can be blocked by colchicine, which inhibits cytoskeleton microtubule formation that is 
required for many endocytic pathways [65-67]. These findings suggest that Stx 1 
translocates in a transcellular manner. Stx 2 translocation, on the other hand, does not 
require energy, and is not blocked by colchicine. This suggests that Stx 2 translocates by a 
paracellular pathway [65]. However, these studies were done zn vzfro in polarized tissue 
cultures, and may or may not represent the wz vzvo translocation of Stx. 
Stx trafficking 
The Stx's, like several other toxins including ricin, a plant toxin from castor beans, and 
cholera toxin, exert their toxic activity in the cytosol of the affected cell [24]. Stx works by 
enzymatically cleaving a specific purine base on the 28s rRNA, which blocks protein chain 
elongation by preventing the peptide elongation factors EF-1 and EF-2 from interacting with 
the rRNA [17, 68, 69]. This rapidly shuts down protein synthesis and results in lethal or 
sublethal cell injury. The cell death that occurs in Stx Induced lethal cell injury is thought to 
be apoptotic [70]. 
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Trafficking of Stx within the target cell is retrograde through the Golgi apparatus to the ER 
[24, 71], and is dependent on Rabl 1 and Rab6a', which are GTP binding proteins [24]. Once 
the toxin reaches the ER, it translocates to the cytosol [24]. In order to become active, the A 
subunit of Stx Is cleaved by an enzyme called F win [72], which is also responsible for 
activating several other protein toxins [73]. Furin is a serine protease that is present in most 
cell types, and is located primarily within the trans-Golgi network, where it cleaves 
precursors of some secretory membrane-bound proteins [74]. 
EHEC earners 
E. co/i 0157:H7 is commonly carried by cattle, which, as adults do not exhibit clinical signs 
of infection and are a large reservoir of infection [75]. Although E. co/z 0157:H7 is not 
pathogenic for adult cattle, it colonizes the ileum and large intestine in young cattle (< 3 
weeks), causing A/E lesions and bloody diarrhea [76]. Pruimboom et al. showed that cattle 
lack vascular receptors for Stx, which likely explains the lack of systemic disease seen in 
infected adult cattle [47]. Recent studies have shown that the bacteria are carried in adult 
cattle on the skin of and immediately surrounding the anus [77]. There is also evidence that 
the bacteria are carried in the mouth of cattle. A recent report shows that ropes tied to fences 
at locations where cattle can easily access and chew become contaminated by & co/z 
0157:H7 in carrier herds [78]. These ropes can be useful for determining the E. co/z 
0157:H7 infection status of a herd. Additionally, watering troughs of herds carrying E. co/z 
0157:H7 also become contaminated [79]. Shedding of E. co/z 0157:H7 is variable 
throughout year, with increased shedding occurring during the warmer months, which 
correlates with increased human infections at this time [80]. 
In addition to cattle, EHECs are found in sheep, goats, and pigs. Some strains of STEC 
have been isolated from avian species, although Vero cell cytotoxicity, a test that detects the 
presence of Stx, in these strains is rare, and none were positive for eae [81]. In the United 
States, the main STEC's in pigs are 0139, 0138,0141, and 0147, which produce Stx 2e and 
causes edema disease [82], although & co/z 0157:H7 has been isolated from pig herds. In 
other countries, like Japan, the incidence of E. co/z 0157:H7 in pigs is actually higher than 
the incidence in cattle. Among non-domestic animals, E. co/z 0157:H7 has been found in the 
feces of deer that co-graze with cattle at a prevalence of 2.4%, suggesting that deer may also 
be a carrier [83]. 
EHEC fransm/ss/on 
EHECs, including E. coZz 0157:H7 are usually transmitted to humans through the food 
supply, although there have been outbreaks that were associated with farm visits, and petting 
zoo visits, as well as person to person transmission (fecal-oral) within families, at daycare 
centers, in nursing homes, and at swimming pools. Within the food supply, the most 
common source of human infection, and the most well known is under-cooked hamburger 
meat. Hamburger is especially dangerous because of the large number of animals that may 
go into a single batch of meat, and the fact that the grinding process mixes the bacteria 
throughout the meat, where it is difficult to detect and is protected from surface heat that kills 
bacteria on other cuts of meat, such as steak. The economic impact of E. co/z 0157:H7 in the 
food supply can be tremendous. Since the U.S. government has adopted a "zero tolerance" 
attitude toward E. co/z 0157:H7, numerous large recalls of meat have occurred throughout 
the U.S. In 2000,2,631,180 pounds of hamburger were recalled in the United States and 
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Canada after being found to be contaminated with & coZz 0157:H7. The average recall was 
for 138,483 pounds of meat [84] 
In addition to hamburger, EHECs have been isolated from unpasteurized milk and cheese 
products, unpasteurized juice products, fruit, contaminated local water supplies, and fresh 
vegetables. In Japan, 526 school children and 35 adults were infected by eating at a 
contaminated salad bar [14]. 
Person to person transmission within families is common, and many times family members 
that carry & co# 0157:H7 are asymptomatic. Detection of infected family members by fecal 
examination showed an approximately 30% infection rate among parents of infected children 
and a 45% infection rate among siblings of infected children, however, another study found 
Stx to be bound to polymorphonuclear white blood cells (PMNs) in 82% of household 
members, vs. 21% who were positive by stool and serum testing [85]. 
EHEC confro/ measures 
Current control measures to detect E. co/z 0157:H7 in the food supply and prevent spread 
include random cultures, PCR, and ELISA tests of the meat supply, washing beef carcasses 
at slaughter, and adequate chlorination of municipal water supplies and swimming facilities. 
Perhaps the most important control measure is public education. The majority of cases of E. 
co/z 0157:H7 infection in the U.S. could be prevented by adequately cooking hamburger 
meat to an internal temperature of 158° F. 
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Intestinal barrier function 
/nfroducf/on 
The gastrointestinal (GI) tract faces the complex, amazing, and contradictory task of 
absorbing the fluids and nutrients required for the maintenance of an organism, while 
preventing absorption of bacteria and bacterial toxins and by-products. This occurs in the 
most bacterially contaminated environment of the body, an environment that contains 
approximately 10^ organisms per ml of contents in the large intestine, and typically has over 
30 genera and over 500 species of identified bacteria [86]. In order to perform it's functions, 
the GI tract has evolved a complex set of mechanisms that allow for nutrient and fluid 
absorption and prevent, for the most part, absorption of harmful substances and colonization 
by harmful organisms. 
The mucosal barrier consists of a collection of simple and more complex mechanisms to 
prevent colonization and bacterial by-product absorption. From the mouth to the anus, the 
alimentary canal secretes fluids and mucous that help to flush would be colonizers away from 
mucosal surfaces. In addition, there is a rapid turnover of cells in the GI tract, so that cells 
that do get colonized rapidly slough and are replaced by new cells. The stomach in 
monogastrics, and the abomasum in ruminates maintain an acid environment that kills most 
of the flora in incoming foods and from the mouth. In the small intestine, enzymes are added 
to the ingesta to aid in digestion, but many of these enzymes also have bacteriocidal and/or 
bacteriostatic activity. In addition, bile salts, goblet cell secretions, and secretory IgA are 
added to the ingesta, and these also have bacteriocidal and/or bacteriostatic activity. 
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/nfesfma/ ce// (ypes 
Crypt cells 
There are multiple types of cells that line the alimentary tract, and each of these cell types 
contributes to barrier function. Crypt cells, so named because they line the small pits or 
crypts within the intestine, are the pluripotent mitotically active cell population within the 
intestine. They give rise to two populations of cells, one of which produces absorptive 
enterocytes, and the other of which produces the secretory cells of the intestine, including 
goblet cells, enteroendocrine cells, and Paneth cells [87]. The basal rate of crypt cell mitosis 
allows for complete turn over of the absorptive enterocytes in the intestine approximately 
every 3-5 days under normal conditions [88]. Intestinal injury stimulates crypt cells to 
proliferate more rapidly in order to replenish the damaged absorptive cells. 
Absorptive enterocytes 
The most numerous cell type in the small intestine is the absorptive enterocvte. These are the 
major absorptive cells in the small intestine, and, as mentioned above, are derived from the 
crypt cells. These cells have numerous (-600) microvilli along the luminal border and are 
anchored to the basement membrane of the intestinal villi [89]. The microvilli increase the 
surface area of the apical membrane of the cell by a factor of 20 [89]. Combined with 
intestinal fold, villi, and microvilli, the surface area of the small intestine is increased about 
600 fold, so that the surface area of the average human small intestine is equal to the surface 
area of a tennis court [89]. Numerous receptors for amino acids and monosaccharides are 
located along the microvilli of intestinal epithelial cells, which allow for transcellular 
absorption of digested food materials [89]. In addition, there are numerous Na/K pumps that 
allow the cell to move electrolytes, and thus fluid, in and out of the cell. 
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Paneth cells 
Paneth cells are intestinal epithelial cells that are located in the crypts and contain 
eosinophilic secretory granules. These granules contain alpha defensins, lysozyme, and 
secretory phospholipase A%, as well as antimicrobial peptides [90]. The granules are released 
from the apical surface of the Paneth cells by regulated exocytosis [91, 92]. Secretion of the 
granules can be stimulated by cholinergic agonists [92]. Paneth cells mature as they migrate 
down into the crypts, and have a lifespan of approximately 20 days [93]. 
Enteroendocrlne cells 
Enteroendocrine cells are formed from the same progenitor as Paneth cells [87], and are 
scattered throughout the intestinal mucosal cells. They function by producing and releasing 
certain hormones, such as glucagon-like peptides [94], serotonin, secretin, and substance P 
[95]. These cells have been shown, in mice, to have at least 15 regionally distributed subsets, 
based upon their primary secreted product [95]. 
Goblet cells 
The mucous layer within the GI tract is produced by goblet cells. These cells originate from 
crypt cells as do the absorptive epithelial cells. Goblet cells are located along the villi 
throughout the GI tract. Histologically they are cup or goblet shaped, as their name suggests, 
and are filled with mucinous material that stains light blue to grey in H&E stained sections. 
Mucous within the GI tract acts as a lubricant to ease the passage of ingesta, and also has a 
protective role. In the stomach, the mucous layer helps prevent damage to the gastric mucosa 
in the acidic environment. In the small intestine, the mucous layer helps prevent 
autodigestion by the enzymes released from the exocrine pancreas. In addition, the 
glycoprotein structure of the mucous layer acts as a trap for bacteria, providing myriad 
binding sites for flagella and other bacterial components. This allows the bacteria, in many 
cases, to be swept away with the mucous layer during normal peristalsis. However, in some 
instances, the mucous layer can actually act as the initial foothold that allows the bacteria to 
colonize the intestinal mucosa [86]. An example of this is the oligomassosides of mucin the 
binds a type I pili produced by certain strains of E. coli Q157:H7 [96]. 
8arr/er funcf/on and profecf/on 
Tight junctions 
Intestinal epithelial cells are joined laterally by "tight junctions", which are electron-dense 
areas at the lateral margins of the cells that are tightly interdigitated. Tight junctions are 
formed by at least two types of proteins that are membrane spanning, occludin and claudin. 
There are at least 20 different members of the claudin family of proteins, all of which are 
involved in tight junction formation. The occludin and claudin proteins are anchored within 
the cytoplasm to the ZO-1 and ZO-2 proteins, which in turn are connected to actin filaments. 
The extra-cellular portions of occludin and claudin form loop structures that interdigitate and 
presumably act like a zipper (reviewed in [97, 98]). Since these molecules are anchored to 
the ZO proteins, which in turn are connected to actin molecules, tight junction permeability 
can be modulated by traction on the associated actin molecules [99,100]. 
The tight junctions are the major site of fluid secretion and absorption in the intestine. The 
fluids move back and forth following relative electrolyte concentrations. Absorption through 
tight junctions is called "para-cellular" absorption. Tight junctions are also the sites through 
which inflammatory cells transmigrate through the mucosa into the intestinal lumen [101]. 
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Although tight junctions are permeable to fluids, under normal circumstances, bacterial 
toxins are not allowed through [99]. 
Innate Immunity & Antimicrobial peptides 
The intestinal mucosa protects itself from pathogens with a variety of innate immune factors, 
including pH, mucus, commensal microflora, and peristalsis as well as secreted products 
such as bile and pancreatic enzymes. More recently, endogenous peptides with antimicrobial 
properties have been discovered [86]. These peptides are divided into the alpha defensins, 
the beta defensins, and cathelicidins. They work by inserting themselves into the membranes 
of their target cells and forming pores that lead to rapid lysis of the cell [102]. The defensins 
currently has the greatest number of known family members. Defensins are peptides that 
contain 29-35 amino acid residues, are cationic, arginine-rich, and contain 3 disulfide bridges 
formed by 6 cysteines [103]. The defensins are divided into alpha and beta defensins, based 
upon the pattern of the disulfide bonding [86]. Alpha defensins include Human Defensin 5 
(HD-5) and Human Defensin-6 (HD-6), and expression appears to be limited to the Paneth 
cells [86]. The beta defensins including LAP, on the other hand, are expressed more widely 
throughout the GI tract. In humans, hBD-1 and hBD-2 are expressed in the GI tract, as well 
as in the lung and other epithelial tissues. Some defensins, such as HD-5 and hBD-1, are 
constitutively expressed, while expression of others, such as HD-6 and hBD-2, are inducible 
[86]. The activity of defensins is tightly regulated by the salt concentration in the 
microenvironment, and is thus active at the borders of the intestinal epithelial cells where it is 
secreted, but not in the lumen of the gut, where salt concentrations are lower. In this way, 
beta defensins act as border guards that attack only those bacteria that closely approach the 
intestinal mucosa. 
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Toll-like receptors 
Intestinal epithelial cells have Toll-like receptors (TLRs) that recognize certain highly 
conserved bacterial components known as pathogen associated molecular patterns 
(PAMPSs), and are involved in identifying bacterial invaders and inducing responses in the 
intestinal epithelial cells [104]. TLR's were discovered in Drosophila, and appear to be 
conserved throughout evolution. TLR's are transmembrane proteins. The extra-cellular 
portion contains numerous leucine-rich motif repeats, which are common to other pattern 
recognition proteins. The cytoplasmic portion of the protein is capable of triggering 
intracellular signals via homology to the IL-1 receptor [105]. TLR activation has been 
shown to result in induction of IL-1, IL-6, IL-8, IL-10, IL-12, and TNF alpha [105]. Through 
the activation of IL-12 and subsequent Th response, TLR's may form a bridge between the 
innate and the adaptive immune system [105]. 
Adaptive Immune system 
The adaptive immune system also plays a role in mucosal barrier function and mucosal 
protection. The adaptive immune system consists of lymphocytes, plasma cells, and antigen 
presenting cells. The intestinal adaptive immune system, like the intestinal tract itself, has a 
somewhat contradictory function. It must respond to non-self antigens in order to protect the 
system, but at the same time, must modulate its' responses so that it does not over react to the 
molecules and flora that are normal residents of the intestinal tract. This is a fine balancing 
act that can have devastating consequences if it tips too far in either direction. Over reaction 
to normal flora and GI contents is thought to be the underlying cause of Crohns disease and 
ulcerative colitis in humans, as well as inflammatory bowel disease (IBD) syndrome in cats 
and dogs. Under reaction of the intestinal immune system can lead to chronic diarrhea, mal­
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absorption, sepsis, and even death of the individual. The mechanisms of control of the 
adaptive immune system in the GI tract is beyond the scope of this literature review, but the 
contribution of immune system to mucosal barrier function will be briefly addressed. The 
adaptive immune system ultimately produces effector cells that kill targeted organisms or 
produce proteins, i.e. immunoglobulins that bind to targeted organisms or molecules. 
Immunoglobulins activate other attack mechanisms, such as the complement cascade, and 
opsonize the molecule or organism for phagocytosis by the innate immune system cells. 
Within the GI tract, immunoglobulin A (IgA) is secreted as a dimer that is linked at the Fc 
portion of the immunoglobulin. IgA functions to specifically target pathogenic bacteria and 
products for degradation. 
/nfesffna/ repa/r 
It is inevitable that the intestinal mucosa will be damaged while performing its absorptive 
and mucosal surveillance functions. The same characteristics that allow the GI tract to 
absorb nutrients and fluids (increased surface area, single cell layer mucosa, etc.) make it 
prone to mechanical, chemical, and biological damage. In the contaminated environment of 
intestinal tract, it imperative that any damage to the mucosa be repaired as quickly as 
possible in order to prevent or limit translocation of unwanted substances into the body. 
There are several mechanisms that the intestinal tract uses to rapidly repair damage. When 
ulceration of the intestinal mucosa occurs, the villi rapidly contract, reducing the villous 
surface area. At the same time, undamaged epithelial cells flatten out and migrate along the 
exposed basement membrane to cover ulcerated areas in a process called restitution. 
Following injury, crypt cell mitosis increases and production of intestinal epithelial cells 
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speeds up, providing cells to replace the damaged cells. The villous will eventually relax and 
return to its' normal size after the defect is repaired. Damaged intestinal epithelium releases 
a variety of cytokines, including IL-8, and TNFa, and CXC chemokines, as well as 
prostaglandins. Prostaglandins produced by the injured tissues contribute to the contraction 
of villi and the epithelial cell restitution mentioned above [106]. Argenzio et al., showed 
that prostaglandins also stimulate barrier function recovery by causing tight junctions to 
close. The prostaglandins apparently accomplish this by increasing the secretion of chloride 
(CI ) and inhibiting reabsorption of sodium (Na^). This induces an osmotic gradient that is 
associated with decreased tight junction permeability [107,108]. In fact, it is the 
prostaglandin mediated closure of tight junctions that restores resistance to injured intestine 
in Ussing chambers rather than restitution of the intestinal epithelium [109]. In addition to 
their functions in restoring mucosal barrier function, the cytokines and chemokines induce an 
inflammatory response, up regulate the innate and adaptive immune systems, and are 
chemotactic for a variety of inflammatory cells, including neutrophils and macrophages. 
These cells defend the border against possible invading organisms and substances while the 
mucosal barrier function is reduced. In some instances, though, the inflammatory cells can 
cause collateral damage. 
Host Inflammatory Response 
Genera/ /nf/ammaffon /n/brmaf/on 
Inflammation is a response of living tissues to physical, chemical, or biologically induced 
damage. The classic inflammatory response, first described by Cornelius Celsus as the 
cardinal signs of inflammation in the first century CE, includes increase in temperature 
(calor), redness (rubor), swelling (tumor), and pain (dolor). The fifth cardinal sign, loss of or 
decrease in function, is attributed to Galen in the second century CE, but many people 
believe it originated with Rudolf Virchow in the nineteenth century CE [110]. The 
inflammatory response has been called a surface oriented response because the process, from 
sensing damage, to initiating cellular responses, to inflammatory cell migration, takes place 
at the cell surface or through receptors and ligands expressed on the surface of cells. 
Inflammation is primarily a vascular response. The swelling, redness, increase in 
temperature, and to some extent the pain and loss of function associated with inflammation 
can be traced to changes in blood flow and vascular permeability that are induced by 
inflammatory mediators. In response to substance P, histamine, and kinins, small blood 
vessels dilate to increase the blood flow, while the vascular endothelial cells contract to allow 
plasma to leak out into surrounding tissues. Likewise, the recruitment of inflammatory cells 
such as neutrophils and macrophages occur at the vascular level. Vascular endothelial cells, 
in response to inflammatory mediators such as IL-8 and TNF express E- and P- selectins, 
which cause circulating inflammatory cells to marginale and roll along the vascular 
endothelium, where they express adhesion molecules such as & integrins that encounter and 
bind to intercellular adhesion molecules (ICAMs) that allow the marginated cells to bind 
more strongly and then migrate through the vessel into the surrounding tissue. 
/nnafe and adapffve /mmun/fy 
Inflammatory leukocytes can be divided into two classes in regards to their contribution to 
immunity: the innate immune cells (neutrophils, macrophages, eosinophils, and basophils) 
and the adaptive immune cells (B and T lymphocytes, and plasma cells). The innate 
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immunity inflammatory cells are further classified as mononuclear cells 
(monocytes/macrophages) and polymorphonuclear cells, or PMNs (neutrophil, eosinophil, 
basophil). Some mammals, such as rabbits, and all avian species have heterophils instead of 
neutrophils, based upon the staining characteristics and enzyme inventory of the granules 
within the predominate PMN population. 
WeufropMs 
Introduction 
The earliest responding inflammatory cell in most mammals, as well as the most numerous, 
is the neutrophil. Neutrophils are formed in the bone marrow from a pluripotent line of stem 
cells. Neutrophils have a short functional life, surviving only 48 to 72 hours after entering 
the circulating pool. If not recruited to an inflammatory site, neutrophils will generally enter 
the intestine, the lung, or the urogenital tract to die, not unlike the mythical elephant burial 
grounds in novels by Edgar Rice Burroughs or J. Ryder Haggard. 
Neutrophil granules 
Neutrophils have several kinds of intracytoplasmic granules that contain different enzymes 
and proteins. The primary granules are the first to appear, and can be found in the 
promyelocyte stage of myelogenesis. These granules contain myeloperoxidase (MPO), 
defensins, and proteinase 3 (PR3), and stain azurophilic. At the metamyelocyte stage of 
development, the secondary or "specific" granules appear. These granules contain 
collagenase, lactoferrin, gelatinase, and other proteins, including bactericidal/permeability-
increasing protein (BPI), which is cytotoxic to gram-negative bacteria at nano molar 
concentrations. Another set of granules known as tertiary or "gelatinase" granules also 
forms. These granules are much like specific granules, but, as their name implies, they 
contain large concentrations of gelatinase. When the neutrophils become mature, they form 
rapidly mobilisable vesicles called secretory granules that have adhesion molecules on their 
membranes and contain PR3 in addition to plasma proteins that are presumably acquired by 
endocytosis. In addition, secretory granules contain Cytochrome b^g, which is essential for 
activation of the NADPH, an enzyme that produces reactive oxygen species. When 
neutrophils are stimulated, the granules are secreted in a defined order. Secretory granules 
are secreted first, followed by tertiary (gelatinase) granules, secondary (specific) granules, 
and primary (azurophilic) granules. Granules can also fuse with phagocytic vacuoles to kill 
bacteria that have been phagocytosed by the neutrophil (reviewed in [111]). 
In addition to enzymes, neutrophils contain anti-microbial peptides including defensins and 
cathelecidins that function by forming pores in the cell membranes of many pathogenic 
bacteria [111]. These peptides work synergistically with BPI. Antimicrobial peptides were 
discussed in the mucosal barrier section of this review. 
Neutrophil migration 
As briefly mentioned above, neutrophils are recruited from the circulating pool by activated 
vascular endothelial cells. When activated, endothelial cells express E-Selectin, and release 
stored P-selectin and the selectin ligand Sialyl Lewis X (SLX) that is stored in Weibel-Palade 
bodies on the surface of endothelial cells [112]. Neutrophils constitutevely express L-selectin 
[113]. L-Selectin from the neutrophils binds with the SLX receptor on endothelial cells, 
while P and E-selectin binds with SLX on the neutrophils. This interaction causes a loose 
binding that "tethers" cells, and allows them to roll along the endothelial surface of the blood 
vessel. While undergoing this slow rolling, the neutrophil can bind more tightly to ICAM 
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molecules. Tight ICAM bonding is mediated through members of the integrin family, 
which are composed of a variable alpha subunit (CD1 la, -b, or -c) and a common beta 
subunit (CD18). CD1 la/CD18, also known as LFA-1, binds to ICAM1 and ICAM2. 
CD1 lb/CD 18, also known as MAC-1, binds to ICAM1, ICAM2, fibrinogen, heparin, and 
factor X. In a mouse model, mice deficient in CD1 lb/CD 18 were able to move neutrophils 
out of blood vessels, while mice deficient in CD1 la/CD 18 were not, suggesting that vascular 
transmigration is more dependent on CD1 la/CD18 than CD1 lb/CD18. In addition to the 
ICAMs, Platelet/Endothelial Cell Adhesion Molecules (PECAMs) are important in vascular 
transmigration. PECAMs bind to alphaybeta; integrins. In most instances, neutrophils 
migrate between endothelial cells, disrupting adherent junctions in the process [114,115]. 
Endothelial adherent junctions are formed by cadherins, which are transmembrane proteins 
that homophilically bind to each other and are anchored by the intra-cellular proteins alpha 
eaten in, beta catenin, and plakoglobin. After binding of the neutrophil to the endothelial 
cell, beta catenin and plakoglobin disappear from the cadherin/catenin complex. Del 
Maschio raised questions as to whether the junction disruption was caused by proteases 
secreted by neutrophils, and suggested that the junction disruption was actually due to intra­
cellular signaling induced by neutrophil binding to endothelial cells [116]. However, 
subsequent studies by Moll et al., suggest that this process is mediated by a neutrophil 
protease rather than a cell signaling event between neutrophils and endothelial cells [117]. 
Another recent study suggests that rather than being disrupted, the vascular endothelial cell 
cadherin adherent junctions were relocated or pushed away from the area of transmigration, 
although the PECAM junctions were opened during neutrophil transmigration [118]. 
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Whatever the case, neutrophils migrate between, and sometimes through [119] endothelial 
cells into the surrounding tissue. 
Once outside the blood vessels, the neutrophils migrate along the surface of cells or 
extracellular matrix by extending pseudopodia expressing & integrins and moving in an 
amoeboid fashion. Neutrophils are chemotactic to small gradients of inflammatory 
mediators, such as IL-8, as well as to bacteria and bacterial products. The chemotaxis and 
recognition of bacteria and their products, such as LPS, occurs via Toll-like receptors. These 
evolutionary conserved receptors recognize conserved sequences of key bacterial 
components or metabolites, and are crucial to target recognition by neutrophils and other cell 
types, including enterocytes, as described previously. 
In order to move through tissues and extra-cellular matrices, neutrophils utilize several 
enzymes including proteases, metalloproteinases, collagenases, and elastases. These 
enzymes allow the neutrophil to move through inter-cellular junctions, including tight 
junctions and adherent junctions as previously mentioned. Intestinal epithelial cells release 
proinflammatory cytokines in response to many stimuli including EHEC infection [120-123], 
although one recent paper claims that STEC suppresses pro-inflammatory cytokine 
production via NF-kB suppression that was dependent on EspB [124]. IL-8, which as 
previously mentioned is released by damaged intestinal epithelial cells and induced and up 
regulated by EHEC, is strongly chemotactic for neutrophils. However, IL-8 concentration 
does not form a gradient within intestinal epithelial cells, i.e. the concentration of IL-8 is the 
same at the basal side of the intestinal epithelial cell as it is at the apical side. This means 
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that, while IL-8 is important in recruiting neutrophils to the site of intestinal epithelial 
infection, it does not induce the recruited neutrophils to cross the intestinal epithelial barrier. 
Neutrophil movement through the mucosal barrier is induced by a gradient of bacterial 
products [123], as well as by a chemokine called pathogen-elicited epithelial chemoattractant 
(PEEC) that is secreted apically by intestinal epithelial cells when they encounter pathogenic 
bacteria [125]. 
Neutrophil induced damage 
While migration of neutrophils and other inflammatory cells is necessary so that they can 
reach the site of inflammation and defend the host, it increases the vulnerability of the host to 
certain methods of attack. 7m Wfro studies have shown that transmigration of neutrophils 
across epithelial surfaces, including intestinal epithelial surfaces, increases the permeability 
of those surfaces to surrounding molecules [101, 126-129]. This disruption of barrier 
function lasts approximately 12-20 hours and is dependent upon the number of neutrophils 
that transmigrate [129]. The disruption of barrier function and increase in permeability is 
related to the disruption of tight junctions by the migrating neutrophils. During this period of 
increased permeability, m vzfro studies have shown that Stx Is one of the molecules that 
moves more rapidly and easily across the intestinal epithelial barrier, which is not surprising 
since Stx 2 apparently transmigrates through the mucosal barrier by the paracellular route 
anyway [65,130]. 
When neutrophils reach the site of inflammation, they react to the inflammatory stimuli by 
engulfing and breaking down the stimulus or by degranulating and releasing their battery of 
defensive weapons into the affected area. While some of the defensive mechanisms 
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employed by the neutrophil, such as the defensins, are target specific, somewhat like smart 
bombs, many other mechanisms, such as lysozyme, the superoxide ions induced by the 
oxidative burst, etc., are indiscriminate, more like hand-grenades. The non-specific defense 
mechanisms frequently injure surrounding host cells and tissues, a phenomenon known as 
"innocent bystander phenomenon", or "collateral damage", to continue the military parallel. 
This self-inflicted damage, like the damage induced by transmigration, can further degrade 
the barrier function when the inflammation is occurring on or in close proximity to the 
mucosal barrier, which is the case in EHEC [131-135]. 
Animal Models 
Several animal models have been used to study EHEC and HUS, including neonatal and 
older calves, adult cattle, mice, rabbits, ferrets, primates, gnotobiotic pigs, newborn 
conventional pigs, and grower pigs [46, 55, 57, 58, 62, 75, 76,136-148]. These models have 
been reviewed extensively [46, 55, 57,58, 62, 75, 76,136-148], and none of the animal 
models is a perfect correlation with human disease. Each has its' advantages and 
disadvantages, especially concerning the role of the inflammatory response. 
Conclusions 
Based upon the observations that 1) EHEC colonizes and is closely adherent to the mucosal 
epithelium in cases of hemorrhagic colitis [54], 2) hemorrhagic colitis is characterized by a 
robust host inflammatory response including neutrophilia in most species effected [11, 76, 
141-143,148], 3) host inflammation and specifically neutrophil infiltration and activation 
increase mucosal permeability [101,126-132,134], 4) there is a discordance between fecal 
Stx titers and risk of HUS [41], but, 5) there is a correlation between inflammatory mediator 
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concentrations, neutrophil infiltration, and risk of HUS in humans [37,38,149], we asked the 
question "does colonic inflammation, and specifically neutrophil infiltration, affect Stx 
absorption in EHEC?" In addition, current animal models do not appear appropriate to 
critically test this question. 
Interestingly, it has been shown that EHEC and human neutrophils can modulate the activity 
of other neutrophils in ways that enhance host disease and, if our hypothesis is correct, could 
increase the risk of HUS. For example, Stx Induces IL-8 and other pro-inflammatory 
chemokine secretion by intestinal epithelial cells, and induces neutrophilia and neutrophil 
activation in the host [121,122,148,150]. This is especially important in light of evidence 
that human neutrophils bind Stx and can transfer Stx to glomerular endothelial cells [151, 
152]. Human neutrophils and the products that they secrete, specifically H2O2, are known to 
stimulate Stx production by prophage induction in EHECs [153]. Additionally, Stx has been 
shown to prolong neutrophil life [154], and induce superoxide production, while impairing 
phagocytosis [155]. All of these host-pathogen interactions increase inflammation or Stx 
production. If inflammation increases Stx absorption, then this is a potent combination of 
events that could increase the likelihood or extent of Stx translocation from the intestinal 
lumen to the systemic circulation and the subsequent development of systemic disease (i.e. 
HUS). 
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Abstract 
Esc&erzc&za co/z 0157:H7, an enterohemorrhagic E. co/z (EHEC), are bacteria that cause 
hemorrhagic colitis and the complicating condition, hemolytic uremic syndrome (HUS) in 
the United States and throughout the world. In EHEC infections, the bacteria colonize the 
mucosal epithelium and remain within the intestinal lumen where they release Shiga toxins 
(Stx), which enter the systemic circulation, and can cause the systemic lesions of HUS. 
Although it is known that HUS is caused by the Shigatoxins Stx 1 and Stx 2, the mechanism 
of Stx movement from the intestinal lumen to the systemic circulation z% vzvo is poorly 
understood. It is our hypothesis that the host inflammatory response to EHEC enhances 
translocation of Stx from the intestinal lumen to the systemic circulation. Newborn pigs (less 
than 24-hrs-old at time of inoculation) infected with E. co/z 0157:H7 develop vascular 
lesions similar to those seen in humans with HUS. However, the newborn pig is capable of 
absorbing macromolecules such as immunoglobulins and Stx until the second or third day of 
life, which limits its usefulness for studying the mechanism of Stx absorption. In this 
experiment we infected 2 and 3-day-old suckling pigs with E. co/z 0157:H7 strain 86-24 or 
non-pathogenic E. co/z 123. Our 3-day-old suckling pigs developed typical attaching and 
effacing (A/E) lesions with & co/z 0157:H7, but lacked a histologically detectable 
inflammatory response and systemic signs of Stx absorption. We therefore concluded that 
the 3-day-old pig can be colonized by E. co/z 0157:H7 without the development of clinical 
signs suggestive of toxin absorption. 
Introduction: 
Diarrheal diseases caused by enteropathogenic Gram-negative bacteria are responsible for 
morbidity and mortality in people who live in both underdeveloped and developed countries 
including the United States. In the U. S., two common causes of severe diarrheal disease are 
&z/fMo»e//a ap. and, more recently, enterohemorrhagic E. co/z (EHEC). These infections are 
contracted through ingestion of contaminated food products, or by fecal oral inoculation from 
other infected individuals (11). During the past decade, EHEC's in general and E. co/z 
0157:H7 in particular have become recognized as a cause of hemorrhagic colitis and the 
associated complicating condition, hemolytic uremic syndrome (HUS) (24). Up to 10% of 
young children affected by E. co/z 0157:H7 may go on to develop HUS, which is the leading 
cause of acute renal failure in children in the U.S. (7,24). Shiga toxins 1 and 2 (Stx 1 and 
Stx 2), produced by & co/z 0157:H7 are responsible for HUS (8, 16, 18, 23,29). These 
structurally similar but antigenically distinct toxins both bind to the Gb; receptor via B 
subunit mediated receptor specificity (16). Studies have shown that the Gbs receptor is 
highly expressed in human glomerular endothelial cells, which likely accounts for their 
exquisite sensitivity to the Stx (18). Stx functions by enzymatically degrading the ribosome, 
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thereby halting protein synthesis and leading to rapid cell death (23). 
Although it is known that Stx is responsible for HUS, it is not known how the toxin crosses 
from the intestinal lumen into the systemic circulation to reach the kidneys, brain, and other 
systemic sites of action m vzvo. 7% vzfro studies have shown the Stx 1 crosses polarized 
intestinal epithelial cells by a transcellular pathway and that Stx 2 crosses polarized intestinal 
epithelial cells by a paracellular pathway (1,14), however, it is not known if these paradigms 
hold z» vzvo. Evidence that the zrz vzvo situation is not this straight forward includes the 
finding that fecal Stx titers do not correlate with the risk of developing HUS (3), which they 
should if Stx translocation z/z vzvo was simply concentration dependant transcellular and 
paracellular translocation. 
EHEC form intimate, tightly adherent attachments, known as attaching and effacing (A/E) 
lesions, to the intestinal epithelial cells of affected individuals (21 ). The bacteria remain in 
the intestinal tract and release Stx that somehow crosses the intestinal mucosal barrier and 
enters the systemic circulation, where it causes systemic disease and systemic vascular 
lesions. Newborn pigs less than 24-hrs of age are susceptible to infection by EHEC and 
develop intestinal A/E lesions and systemic vascular lesions similar to those seen in humans 
by 24 to 36 hours after infection (2, 6,19,25). This makes neonatal pigs an appropriate 
animal model for human EHEC infections. However, the intestinal tract of newborn pigs is 
capable of absorbing certain large molecules, such as immunoglobulins, intact for the first 48 
to 72 hours of life (26-28). This process, called passive transfer of maternal antibodies, 
provides newborn pigs with passive immunity for the first 2 to 3 months of life (26). 
Previous studies have used pigs less than 24 hours of age to study the systemic effects of Stx 
(6,13). Although this approach has worked well to define the systemic effects of Stx, 
passive transfer limits the usefulness of the newborn (<24-hr-old) pig in studies of the 
mechanism of absorption of Stx, since Stx appears to be passively absorbed along with 
immunoglobulin and other colostral proteins (6). 
In order to study the mechanism of absorption of Stx 2 from the intestinal lumen to the 
systemic circulation in pigs, we determined the effect of EHEC infection in 3-day-old pigs. 
The advantage of the 3-day-old pig versus the newborn pig model is that by three days, 
passive transfer of maternal antibodies and other intestinal macromolecules has ceased, and 
thus is not a complicating factor (26. 27). To the best of our knowledge, EHEC infections in 
pigs inoculated at three days of age have not been reported. In this study, we demonstrated 
that 3-day-old pigs were readily colonized by EHEC and developed typical A/E lesions in the 
cecum, spiral colon, and to a lesser extent, the rectum. 
Materials and Methods: 
Animals 
All procedures and treatments were approved by the Iowa State University Animal Care and 
Use Committee. Bred York/Duroc cross sows were obtained from Atlantic pig farms in 
Atlantic, Iowa. The sows were placed in a biolevel 2 holding facility at Iowa State 
University in Ames, Iowa at least a week before the scheduled farrowing date to allow the 
animais to acclimate. At 3 days before the scheduled farrowing date, the pigs were placed in 
standard farrowing crates. The sows were monitored 5 times per day and allowed to farrow 
naturally. Farrowing date was designated as either the day the sows were seen farrowing, or 
the morning that the piglets were discovered with sows that farrowed overnight (last 
observation time, 9 PM). The average litter size was 10 piglets (range 9-13). One sow 
delivered 13 piglets. Of these, the three smallest piglets were removed from the study to 
maintain consistent piglet size. 
Piglets were allowed to suckle for the entire length of the experiment. At 2 days (Groups C 
and D, n-20 pigs) or 3 days (Groups A and B, n=20 pigs) of age the piglets were numbered 
with a paint stick and inoculated with 10s CFU of EHEC E. coli 0157:H7 strain 86-24, an 
Stx 2+ and eae+ strain that has been used in studies of EHEC infection in pigs (6). Control 
litters (n=16 pigs) were inoculated with 108 CFU of the non-pathogenic E. coli strain 123. 
Observations 
Throughout the experiment, diarrhea, activity level, and clinical signs of central nervous 
system lesions (incoordination, head pressing, seizures, and paddling) were recorded daily. 
Blood Samples 
Blood samples were collected in EDTA and serum tubes by anterior venous sinus 
venipuncture immediately prior to inoculation and immediately prior to euthanasia at 4 days 
post-inoculation (day 6 or 7 post-partum respectively). These samples were analyzed for Stx 
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activity using the Vero cell assay as previously described (9). 
Tissue collection 
The pigs were euthanized by pentobarbital overdose (Beuthanasia, Schering Plough, Union) 
on day 4 post-inoculation (day 6 or 7 post-partum respectively). Necropsies were performed 
on all pigs and samples of jejunum, ileum, cecum, spiral colon, rectum, kidney, and brain 
were collected in 10% neutral buffered formalin for histologic examination. 
Histologic exam 
Histologic samples were fixed in 10% neutral buffered formalin for 24 hours and then 
embedded in paraffin. Paraffin embedded blocks were cut in 5 /mi sections, adhered to a 
glass slide and stained with hematoxylin and eosin (H&E). H&E stained histologic sections 
were examined for colonization by A/E bacteria, and inflammation (Fzgwre 7). Inflammation 
was defined as edema, congestion, and/or neutrophil infiltration in the lamina propria, 
intestinal epithelial cells, or intestinal lumen. Loss of apical cytoplasm was judged present 
when the lumenal cytoplasmic border of enterocytes with adherent bacteria was appreciably 
recessed as compared to the lumenal cytoplasmic border of adjacent enterocytes without A/E 
lesions. Colonization was judged to be present in a pig if adherent bacteria that stained for E. 
co/f 0157:H7 antigen by immunohistochemistry (see below) were present in one or more of 
the following: ileum, cecum, spiral colon, or rectum. 
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Immunohistochemistry 
E. coli 0157:H7 bacteria were detected and identified by immunohistochemical staining 
using an Optimax Plus stainer (Biogenics, San Ramon, CA) using a modified protocol 
developed by Dean-Nystrom et al. (4). Briefly, paraffin embedded sections were cut to 5 jum 
and adhered to glass slides. 5 pm sections were de-paraffinized in xylene and re-hydrated 
through a series of ethanol/water baths. De-parafGnized sections were incubated with 3% 
hydrogen peroxide for 30 minutes to block peroxidase activity. The sections were then 
rinsed in Tris-buffered saline containing 0.05% Tween (TBS-T20) (Sigma, St. Louis, MO). 
Using a wax pen (Pap-pen, Biogenics, San Ramon, CA), two lines were drawn on the glass 
slide, one above and one below the section, to prevent excessive spreading of the reagents 
and tissue drying. The slides were loaded into the slide processor and a previously optimized 
staining protocol was run (4), The slides were incubated with 1:20000 dilution of affinity 
purified goat anti-& co# 0157:H7 polyclonal antibody (Kirkgaard-Perry, Gathersburg, MD) 
2 times for 45 minutes, and rinsed in TBS-T20. Biotinylated rabbit-anti goat antibody was 
used as a secondary antibody (Kirkgaard-Perry). Signals were developed using the Nova 
Red substrate system (Vector Laboratories, Burlingame, CA). The slides were counter-
stained with hematoxylin. Negative controls were processed using the same technique, but 
primary antibody in the incubation step was replaced by incubation with TBS-T20. In 
addition, the normal bacterial flora within the intestinal lumen provided an internal control, 
since only adherent bacteria and occasional individual bacteria in overlying mattes stained 
positive. 
Immunohistochemically stained sections (3 sections/pig/region of intestine) of ileum, cecum, 
spiral colon, and rectum were scored for attaching and effacing lesions to determine 
colonization (Fzgwre 2) by the following: 0= no A/E lesions; 1= sections with A/E lesions 
present and covering 10% or less of the mucosal surface; 2= sections with A/E lesions 
affecting between 10% and 30% of the mucosal surface; 3= sections with A/E lesions 
affecting between 30% and 50% of the mucosal surface; and 4= sections with A/E lesions 
affecting >50% of the mucosal surface. 
Results: 
Colonization 
Four groups of pigs (A, B, D, and E, n = 10,10,11, and 9 respectively) were inoculated with 
E. co/z 0157:H7 strain 86-24. Of these, 26 (65%) had colonization at the time of necropsy 
(.Figure 3).The amount of colonization ranged from less than 1% of the section affected to 
approximately 50% of the section affected. Site of colonization varied by age of pig at the 
time of inoculation. Pigs inoculated at two days of age were colonized in the cecum and 
spiral colon, but not the rectum. Pigs inoculated at three days of age were colonized in the 
cecum, spiral colon, and rectum (Fzgwre 4). Pigs inoculated at 2 days of age had greater 
average colonization than pigs inoculated at three days of age (Fzgwre J). Colonization was 
not seen in the jejunum or ileum of treatment pigs. Loss of apical cytoplasm in association 
with colonization was seen in 18/26 (69%) of the colonized pigs. No colonization was seen 
in control pigs inoculated with E. co/z strain 123. 
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Inflammation 
Histologically, inflammation was detected in 4/40 infected pigs (10%), but when present was 
not locally associated with areas of & co/z strain 86-24 colonization. The inflammation was 
characterized by small clusters of neutrophils located within scattered, dilated crypts (crypt 
abscesses). Inflammation in control pigs was similar in severity and distribution to that seen 
in the infected pigs. 
Clinical signs of systemic lesions 
No clinical signs or systemic lesions (gross or microscopic) of Shiga toxicosis were seen in 
any of the pigs infected with E. coli strain 86-24 or controls. Clinical signs in the treatment 
piglets and controls were limited to a mild, transient diarrhea that started on day 2 or 3 post-
inoculation and cleared spontaneously by day 4 post-inoculation. The Vero cell assay did not 
detect Stx In the blood of any pig, whether infected with E. coli 0157:H7 strain 86-24 or E. 
coli strain 123. 
Discussion: 
Both 3-day-old suckling pigs, and 2-day-old suckling pigs were readily colonized by E. co/z 
0157:H7 strain 86-24 and, by 4 days post-infection, developed attaching and effacing lesions 
in the cecum, spiral colon, and, depending on the age of the pig at the time of inoculation, in 
the rectum. In spite of the fact that 2 and 3-day-old pigs were colonized, they did not 
develop a histologically detectable host inflammatory response, they lacked Stx In the blood 
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at levels detectable by the Vero cell assay, and they did not develop the signs of systemic Stx 
toxicosis that were seen in pigs inoculated before 24 hours of age (6). 
The lack of host inflammatory response in the face of colonization by EHEC in our pigs is 
puzzling, but is consistent with the results seen in <24 hour piglets (6). The results of this 
study are consistent with the hypothesis that Stx Is absorbed along with colostrum in <24 
hour old pigs. Dean-Nystrom et al. have shown that suckling newborn pigs given & coZ; 
Q157:H7 strain 86-24 at less than 24 hours of age develop CNS signs of Stx toxicosis and 
die rapidly (by 36 hours post-inoculation), sometimes before colonization was detectable (6). 
By contrast, Caesarian-derived/colostrum-deprived (CDCD or gnotobiotic) pigs inoculated at 
less than 24 hours of age did not develop systemic signs of Stx toxicosis until up to 72 hours 
post-inoculation (4-6,25), suggesting that Stx is being co-absorbed with colostral proteins in 
the newborn pig. 
A possible explanation for the apparent lack of Stx absorption seen in our pigs, if one 
hypothesizes receptor mediated transfer as an m vivo Stx translocation pathway, is a change 
in receptor expression in intestinal epithelial cells between birth and three days of age, 
although this does not explain the difference in suckling vs. CDCD pigs seen by Dean-
Nystrom et al. (6). 
Alternatively, it is possible that other factors such as the host inflammatory response play a 
role in changes in mucosal barrier function that allow Stx to be absorbed into the systemic 
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circulation. The intestinal inflammatory response involves the movement of neutrophils and 
other inflammatory cells into the intestinal lumen. During migration, these cells disrupt the 
tight junctions between intestinal epithelial cells resulting in increased intestinal permeability 
to ions, markers such as [^CrjEDTA, and certain sugars (20,22). In addition, antimicrobial 
and proteolytic enzymes released by activated neutrophils can cause "innocent bystander" 
damage to intestinal epithelial cells, further degrading mucosal barrier function (12). Some 
studies in human medicine have described a correlation between circulating cytokine 
inflammatory mediator concentration and the severity of renal lesions in HUS (17), and 
others have found peripheral neutrophilia to be a risk factor for HUS development in cases of 
hemorrhagic colitis (10). Hurley et. al have shown that neutrophil migration across polarized 
intestinal epithelial cells increases Stx translocation in vifro (15), and it is possible that 
neutrophil migration could have a similar effect in vivo. Since neonatal pigs have relatively 
low numbers of neutrophils, and our pigs apparently lacked a host inflammatory response, 
they may have been resistant to Stx translocation. This explanation is consistent with Hurleys 
findings that Stx movement across polarized intestinal epithelial cells in vitro is enhanced by 
the movement of neutrophils across the cells (15). Hurley and Acheson speculated that 
paracellular movement of Stx Is increased by neutrophil mediated temporary disruptions 
vzfro (15). We hypothesize that a similar mechanism may occur m vivo. 
The apparent lack of a host inflammatory response makes the 3-day-old pig a good model to 
study the effect of induced inflammation on Stx translocation. A method of reliably inducing 
an inflammatory response in the cecum and colon of young piglets would allow m vivo 
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comparison of Stx absorption across inflamed vs. non-inflamed intestinal mucosa. 
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List of Figures 
Figure 1. Cecum of a pig infected with E. coli Q157:H7 attaching and effacing (A/E) lesions 4 days after 
inoculat ion. Note the lack of in IIanimation associated w ith A/E colonization. H&E stain. 
Figure 2. Section of cecum from a pig infected with E. coli 0157:1174 days after inoculation. The dark brown 
staining along the margin is antigen of E. coli 0157:117 in sites of attaching and effacing (A/E) lesions. 
Hematoxylin counterstain. 
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Group T reatment A&E Inflammation Cytoplasm Loss Clinical Signs of Systemic Lesions Blood Stx 
A 8624 9/10 4/10 6/10 0/10 0/10 
B 8624 3/10 0/10 1/10 0/10 0/10 
C 123 0/10 2/10 NA 0/10 0/10 
D 8624 9/11 0/11 7/11 0/11 0/10 
E 8624 5/9 0/9 3/9 0/9 0/10 
F 123 0/10 0/10 NA 0/10 0/10 
Figure 3. Number of pigs in each treatment group (A-F)(see Materials and Methods) that have attaching and 
effacing (A/E) lesions, inflammation detectable by light microscopy, intestinal epithelial cytoplasm loss 
secondary to A/E lesions, and detectable blood shiga toxin (Six) via Vero cell assay. 
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Figure 4. E. coli 0157:117 attaching and effacing (A/E) colonization score in the rectum of pigs based upon age 
at time of innoculation. Pigs inoculated at 2 days of age did not have A/E lesions in the rectum, while pigs 
inoculated at 3 days of age had A/E lesions in the rectum. The difference is significant (p=0.026). The colors 
represent the proportion of animals with each colonization score (0-5Xsee Materials and Methods). 
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Figure 5. Colonization scores of E. coli 0157:H7 of pigs based upon age (2 & 3 days) at time of innoculation. 
The colors represent the different colonization scores (0 - 4)(see Materials and Methods). Two day old pigs had 
significantly greater colonization scores ( p=0.06) versus three day old pigs. 
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Chapter 3: DSS induces suppurative and ulcerative inflammation 
in the large intestine of colostrum-fed neonatal pigs. 
A paper prepared for submission to the journal Pefermaf}' PafAo/ogy 
Morgan, T.W., Ackermann, M.R. 
Iowa State University Dept of Vet Pathology 
Abstract 
Previously, we have developed a 3-day-old pig model of & co/i 0157:H7 infection in which 
pigs are colonized by E. co/i 0157:H7 and develop classic attaching and effacing type 
lesions, but develop neither a microscopically detectable host inflammatory response nor 
systemic signs or lesions of Shiga toxin (Stx) absorption. A method of reliably inducing a 
host inflammatory response in the large intestine of neonatal pigs is needed to test the 
hypothesis that the host inflammatory response may influence absorption of Stx. Dextran 
Sulfate Sodium (DSS) induces suppurative inflammation and ulceration in mice, rats, and 
guinea pigs. In this study, we showed that DSS at concentrations of 2.5% in 20 mis of milk 
replacer consistently induced fibrinosuppurative inflammation and ulceration in the ileum, 
cecum, and large intestine of neonatal pigs in a time and dose-dependent manner by 3 days 
post ingestion. DSS consistently induced hemorrhagic colitis by 4 days post-ingestion (8/8 
pigs), which became more severe by 6 days, at which time the pigs had severe suppurative 
inflammation and ulceration in the cecum, spiral colon, and rectum. Similar changes were 
seen in the ileum but were limited to the mucosal epithelium that covered the Peyer's patches. 
This work demonstrates that DSS consistently induces acute inflammatory lesions in the 
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large intestines of pigs. 
Introduction: 
Diarrheal diseases are an important cause of morbidity and mortality in both developed and 
developing countries throughout the world. It is estimated that every year, 2.1 million 
children under the age of 5 die of diarrheal diseases worldwide. In the United States and 
other developed countries, many people suffer from non-infectious diarrheal diseases, such 
as Crohn's disease and other chronic inflammatory bowel diseases. A better understanding of 
the mechanism of bowel inflammation and it's contribution to diarrheal diseases is essential 
to developing treatments and cures for both infectious and non-infectious diarrhea. Animal 
models of acute and chronic diarrheal disease currently include the mouse the rat \ and 
other animals \ In several animal models, Dextran Sulfate Sodium (DSS) has been used to 
induce bowel inflammation and ulcerative colitis. Studies have shown that DSS given in the 
drinking water induces suppurative and ulcerative colitis in mice2,9, rats 3, and guinea pigs6. 
In addition, several studies suggest that the ulcerative colitis induced by DSS in rats and mice 
can be attenuated by suppressing neutrophil function and/or infiltration Since our 
previously developed 3-day-old pig model lacks both a histologically detectable host 
inflammatory response and systemic signs of Stx absorption a method of reliably inducing 
hemorrhagic colitis in neonatal pigs would be ideal to study the role of the host inflammatory 
response to Stx absorption in E. co/z 0157:H7 infection and could be useful as a model of 
other inflammatory bowel diseases. In this study, we tested the ability of various doses of 
DSS to induce inflammation and ulceration in the large intestine of neonatal pigs. The 
purpose of this study was to: 1) determine if DSS caused intestinal inflammation in pigs, 2) 
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characterize these changes, and 3) determine the extent to which DSS-induced inflammation 
alters mucosal permeability. 
Materials and Methods: 
All procedures were approved by the Iowa State University Animal Care and Use 
Committee. Neonatal Yorkshire/Durok cross pigs (<24 hrs) were obtained from a local 
producer (Laboratory Animal Resources, ISU). The pigs were farrowed in crates and 
allowed to suckle prior to removal within 12 hours from the sow in order to obtain colostral 
antibodies through passive transfer. Pigs were placed in stainless steel cages in a climate-
controlled room and cages were maintained at 94° F. The pigs were fed Esbilac (Pet Ag) 
puppy milk replacer. 
Initial range finding studies of 16 pigs showed that DSS dosages of 1% in 20 ml milk 2 times 
daily did not consistently induce inflammation by 6 days of dosing, and that DSS dosages of 
7.5% twice daily consistently induced 100% ulceration with severe inflammation in pigs by 6 
days of dosing (data not shown). Additionally, time trial studies showed that histologic 
inflammation started appearing between days 2 and 4 in pigs dosed with greater than 1% 
DSS 2 times daily (data not shown). 
Treatment pigs were randomly divided into low dose and high dose DSS groups. Low dose 
groups received 2.5% DSS in 20 ml milk replacer 2 times daily (n=2) or 5% DSS in 20 ml 
milk replacer once daily (n=2) starting at day 2 of age. High dose pigs received 5% DSS in 
20 ml milk replacer 2 times daily (n=2) or 7.5% DSS in 20 ml milk replacer once daily (n-2) 
starting at day to of age. 
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The pigs were monitored for food intake, activity level, diarrhea, grossly visible fecal blood, 
and hydration status. The average daily intake was normalized by considering the intake on 
the first day of dosing as 100% for each group. The pigs were dosed in the evening on the 
first day, so dosing did not affect intake for that day. Subsequent daily intake was compared 
to the intake from the first day of dosing. 
Pigs were euthanized at 6 days after the start of DSS treatment. Complete necropsies were 
performed and samples of jejunum, ileum, cecum, spiral colon, and rectum were collected in 
10% neutral buffered formalin for histologic examination. 
At necropsy, the gastrointestinal (GI) tract was evaluated for signs of enteritis including 
spiral colon edema, mucosal hemorrhage, and intestinal discoloration. Sections of ileum, 
cecum, spiral colon, and rectum (3 sections of each tissue per pig) were evaluated 
histologically and were subjectively scored for degree of inflammation and ulceration. 
Inflammatory changes were scored as follows: l=minimal infiltration of inflammatory cells, 
2=mild infiltration of inflammatory cells, 3=moderate infiltration of inflammatory cells, 
4=severe infiltration of inflammatory cells. Degree of ulceration was scored as follows: 
0=ulceration of less than 1% of the mucosal surface, l=ulceration of from 1-20% of the 
mucosal surface, 2=ulceration of 21-40% of the mucosal surface, 3=ulceration of 41-60% of 
the mucosal surface, 4=ulceration of 61-80% of the mucosal surface, 5=ulceration of greater 
than 80% of the mucosal surface. 
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Statistical analysis was performed using JMP 5.0.1a statistical analysis software. Parametric 
data was analyzed using analysis of varience (ANOVA). Non-parametric data was analyzed 
using non-parametric ANOVA. 
Results: 
DSS reliably induced grossly visible fecal blood by 4 days post inoculation at concentrations 
of 2.5% and greater in all pigs. The amount of fecal blood increased from day 4 on in all 
pigs (n=8). The appetite and activity level of the pigs decreased starting at day 3 post-DSS 
dosing and declined as long as pigs were dosed with DSS. By day 7, all treated pigs were 
dehydrated, weak, and lethargic with poor appetites (Figure 1). 
At necropsy, the spiral colons of all treatment pigs were variably edematous with red to dark 
purple discoloration of the serosal surface (Figure 2). The serosal surface of the cecum and 
rectum were similarly discolored in treatment pigs, and there was consistent, but less severe 
edema of the mesorectum. 
Histologically, an inflammatory infiltrate consisting mostly of neutrophils with fewer 
macrophages, lymphocytes, and plasma cells within the lamina propria, mucosa, and 
intestinal lumen of the ileum, cecum, spiral colon, and rectum of all pigs that received DSS. 
The degree of neutrophil infiltration varied by site and dosage of DSS in the ileum and spiral 
colon. 
In low dose groups that received DSS 2.5% BID or 5.0% SID in 20 ml milk replacer, the 
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cecum and large intestinal sections were characterized by infiltration of neutrophils, 
macrophages, lymphocytes, and plasma cells into the lamina propria. There was villous 
atrophy throughout the sections with transmigration of neutrophils across flattened mucosal 
epithelium. In some areas, the mucosal surface was ulcerated and covered by a mixture of 
neutrophils, fibrin, and necrotic cell debris that also extended over non-ulcerated areas in 
some sections (Figure 3)(Figure 4). The villous atrophy and inflammation in the ileum was 
limited to the mucosa directly above the Peyers patches. No lesions were seen in the jejunum. 
The high dose groups received DSS 5.0% BID or 7.5% SID in 20 ml milk replacer. In this 
group, the sections were characterized by near 100% ulceration and necrosis of the mucosal 
surface. The luminal surface of the intestine was composed of a thick layer of necrotic cell 
debris, fibrin, and inflammatory cells (fibrino-necrotic membrane) that replaced the entire 
lamina propria and extended almost to the tunica muscularis in some sections (Figure 
5)(Figure 6). As was seen in the low dose group, the changes in the ileum were limited to the 
mucosa directly above the Peyers patches. The jejunum lacked lesions throughout the 
experiment. 
The high dose DSS group had significantly greater ulceration (p<0.0001) (fzgwre 7) and 
significantly greater inflammation (pcO.OOOl) (Figure 8) than the low dose group. 
Additional studies: 
After determining an initial concentration of 2.5% DSS, based upon the results of this 
experiment (below) 48 additional pigs have been treated with 2.5% DSS in 20 ml of milk 
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with similar results. 
Discussion: 
Dextran Sulfate Sodium (DSS) reliably induces suppurative and ulcerative inflammation in 
the cecum, spiral colon, and rectum of neonatal pigs by 4 days of treatment, in a 
concentration and time dependent manner. The changes induced by DSS in neonatal pigs in 
this experiment were similar to those described in rats, mice, and guinea pigs, and included 
inflammatory cell infiltrates, mucosal cell death, ulceration, and crypt dilation. DSS 2.5% in 
20 ml milk replacer twice daily reliably induced hemorrhagic colitis in all neonatal pigs by 3 
days post-inoculation. The DSS induced colitis was characterized by severe suppurative 
inflammation, ulceration, and hemorrhage of the cecum, spiral colon, and rectum. Changes 
in the small intestine were less severe than those in the large intestine, and were limited to the 
areas directly above the Peyer's patches in the ileum, but were otherwise similar to the large 
intestinal changes. The degree of inflammation and ulceration between the high dose and the 
low dose DSS groups was significant (p<0.0001 for both inflammation and ulceration). 
In the previously described hosts, DSS was added to the drinking water. Due to the expense 
of DSS, it was not feasible to add the material to all of the fluid (milk) that was consumed by 
the pigs. However, we found that DSS worked well when mixed in a relatively small volume 
of milk (20 mis) and administered twice daily. 
The dose of 2.5% DSS twice daily induced a considerable amount of inflammation and 
ulceration without destroying the entire mucosal surface, as happened in the higher doses. 
84 
The effective concentration of DSS used in our studies (2.5%) was similar to the 
concentrations used in studies on guinea pigs (3%), but somewhat lower than the 
concentrations used in rats (4%), and mice (5%) 
In previous studies, we have shown that 3 day old piglets infected with E. co/i 0157:H7 
develop classic attaching and effacing lesions, but lack both a host inflammatory reaction to 
the infection and systemic signs and lesions of Shiga toxin absorption By using DSS to 
induce hemorrhagic colitis in the neonatal pig, we plan to study the contribution of the host 
inflammatory response to Stx absorption in piglets. 
When neutrophils migrate across mucosal surfaces in the intestine, the tight junctions 
between the mucosal cells, which provide much of the barrier function of the intestinal 
mucosa, are temporarily disrupted either by proteases within the neutrophil or by intracellular 
mechanisms within the mucosal cells that are induced by the signals from the neutrophil 
i,u,i3,i4,i6 jn vj[r() studieS have shown that neutrophil migration across polarized mucosal 
cell cultures disrupts the tight junctions, leading to increased mucosal permeability In 
addition, areas of mucosal ulceration are known to allow increased movement of electrolytes 
and other materials between the underlying lamina propria and the intestinal lumen, although 
mucosal ulceration and villous contraction may also decrease bacterial attachment in EHEC 
infections. It seems reasonable to assume that ulceration and inflammation related disruption 
of mucosal barrier function may contribute to increased Stx translocation from the intestinal 
lumen to the systemic circulation in & coZz 0157:H7 infections. Indeed, several studies have 
shown that increased peripheral neutrophilia, increased circulating pro-inflammatory 
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cytokines, and increased fecal excretion of neutrophils are associated with an increased risk 
of developing HUS in humans 
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Figure 1. Daily food intake normalized to first day of treatment (see Materials and Methods). The high 
dose group recieved dextran sulfate sodium (DSS) 5.0% two times daily (n=2) or DSS 7.5% once daily 
(n=2). The low dose group received DSS 2.5% two times daily (n=2) or DSS 5.0% once daily (n=2). The 
error bars represent the standard error of the mean. There was a trend for high dose treatment pigs to 
consume less food by the end of the experiment, but the trend was not significant (p=0.13). 
Figure 2.Gross photograph of the spiral colon from a pig treated with 2.5% dextran sulfate sodium (DSS) 
day 6 of DSS treatment. Note the dark purple discoloration of the spiral colon and gelatinous appearance of 
the mesocolon, due to edema. 
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Figure 3. Photomicrograph (20 x) of spiral colon from a pig treated with low dose (2.5%) dextran sulfate 
sodium (DSS) at day 6 of DSS treatment. There are extensive areas of ulceration that border an area of 
intact mucosal epithelium H&E stain. 
Figure 4. Photomicrograph (40 x) of the spiral colon of a pig treated with low dose (2.5%) dextran sulfate 
sodium (DSS) at day 6 of treatment. There is intense neutrophil infiltration in an ulcerated area, and in an 
area of intact: mucosal epithelium. H&E stain. 
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Figure 5. Photomicrograph ( 1 Ox) of spiral colon from a pig treated with high dose (7.5%) dextran sulfate 
sodium (DSS) at day 6 of DSS treatment. The normal mucosal surface is replaced by a thick fibrino-
necrotic membrane and there is complete loss of mucosal epithelium. H&E stain. 
Figure 6. Photo micrograph (40 x) of the spiral colon of a pig treated with high dose (7.5%) dextran sulfate 
sodium (DSS) at day 6 of DSS treatment. A thick fibrino necrotic membrane has replaced the normal 
mucosal epithelium and there is total loss of mucosal epithelium. H&E stain. 
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Average Ulceration by Treatment 
Figure 7. Mosaic plot of the average ulceration score for animals treated with high dose (5% 2x/day or 7.5% 
I x/day) dextran sulfate sodium (DSS)(n=4) or low dose (2.5% 2x/day or 5% 1 x/dav) DSS (n-4). The high 
dose group had significantly greater ulceration (p<0.0001) than the low dose group. The colors represent 
the different ulceration scores (0-5)(see Materials and Methods). 
Average Inflammation by Treatment 
Treatment 
Figure 8. Mosaic plot of the average inflammation score for animals treated with high dose (5% 2 x/day or 
7.5% 1 x/day) dextran sulfate sodium (DSS)(n=4) or low dose (2.5% 2x/day or 5% 1 x/day) DSS (n-4). The 
high dose group had significantly greater inflammation (pO.OOOl) than the low dose group. The colors 
represent the different inflammation scores (l-4)(see Materials and Methods). 
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Chapter 4: Effect of intestinal inflammation on Stx 2 absorption 
and Stx-induced extra-intestinal lesions m Wvo. 
A paper prepared for submission to the journal T/z/êcfzo» T/M/Mwnzfy 
T. Morgan, J. Gallup, M.Ackermann 
Iowa State University Department of Veterinary Pathology 
Abstract 
Previous studies have shown that E. co/z 0157:H7 readily colonizes 3-day-old pigs, but does 
not induce histologically detectable inflammatory changes, and does not cause clinical signs 
of Shiga toxin (Stx) toxicosis. Dextran Sulfate Sodium (DSS) reliably induces suppurative 
and ulcerative inflammation in the cecum, spiral colon, and rectum of neonatal pigs by 4 
days of treatment, in a concentration and time dependent manner. In this study, the effect of 
mucosal inflammation induced by DSS on systemic signs, absorption of marker sugars, and 
lesions of Stx toxicosis was determined in pigs either infected with E. coli 0157:H7 or dosed 
with E. cofz 0157:H7 crude Stx toxin preparation. Colostrum-fed pigs with and without DSS 
treatment were inoculated with 10* CPU of E. co/z 0157:H7 at 3 days of age or were orally 
dosed with & co/z Q157:H7 crude toxin preparation containing 10^ CD 50/ml of Stx at 4 to 8 
days of age. The strain of E. co/z 0157:H7 strain 86-24 that we used is a spontaneous 
Streptomycin resistant mutant, and in order to determine the effect of commensal microflora 
on& co/z 0157:H7 strain 86-24 colonization, another group of pigs received Streptomycin 
prior to and during & co/z inoculations. All pigs inoculated with E. co/z 0157:H7 developed 
attaching and effacing (A/E) lesions and those receiving DSS developed inflammatory 
lesions and had increased levels of absorption of marker sugars, indicating increased mucosal 
permeability. However, only pigs dosed with crude toxin preparation developed clinical 
signs of Shiga toxicosis. Treatment with DSS did not affect the number of periodic acid 
Schiff (PAS) stained droplets surrounding blood vessels in the medulla, or the rate of micro-
hemorrhage development in the cerebellar folia, cerebellar pons, or medulla. Thus, the 
inflammatory response induced by DSS did not exacerbate signs and lesions of Shiga 
toxicosis. We conclude that severe enteric mucosal inflammation does not enhance Stx 
translocation vzvo. 
Introduction: 
Infections with enterohemorrhagic E. co/z (EHEC) are a common cause of Hemorrhagic 
Colitis (HC) and Hemolytic Uremic Syndrome (HUS) in the United States and around the 
world (16 ). HUS caused by EHEC infections is the leading cause of acute renal failure in 
children in the U.S. and the developed world (11, 18, 34). EHEC bacteria, including E. coli 
0157:H7, form intimate, attaching and effacing (A/E) lesions with enterocytes (23), and 
produce Shiga toxins (Stx), which are responsible for the systemic signs of HUS (7, 20, 31, 
44). V» vzfro studies have shown that neutrophil infiltration enhances mucosal permeability 
(26, 27) (8,12, 29), and increases movement of Stx across polarized epithelial cells (14). In 
humans, and some animal species, EHEC infection is associated with an intense 
inflammatory response that includes neutrophil infiltration, ulceration, and hemorrhage (9, 
17, 35,45). Although pigs are infected with EHEC, the infection is typically not associated 
with an intense inflammatory response. In previous studies we found that pigs older than 3 
days of age that are infected with & co/z 0157:H7 were colonized, but lacked a histologically 
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detectable inflammatory response compared to age matched controls, and did not develop 
systemic or neurologic symptoms of Stx intoxication (25). By contrast, pigs infected before 
3 days of age typically develop clinical and histologic extra-intestinal signs of Stx toxicosis, 
although they also lack a histologically detectable host inflammatory response (3,4,13), 
which may be due to the fact that physiological absorption of macromolecules occurs until 3 
days of age in the pig (42,43). 
Since young pigs are susceptible to systemic Stx toxicosis (3,4,13), but 3 day old pigs do 
not develop an inflammatory response to EHEC infection, and do not develop systemic signs 
of Stx toxicosis, 3 day old pigs are a reasonable model to test the role of inflammation in Stx 
absorption. Dextran Sulfate Sodium (DSS) has been used to cause inflammation in the 
intestine of guinea pigs, rats, and mice (6,10,15,19). We previously showed that DSS 
reliably induces suppurative inflammation, ulceration, and hemorrhage in the cecum, spiral 
colon, and large intestine of neonatal pigs (24). In the current studies, DSS-induced 
inflammation was used to compare clinical signs and histopathologic lesions of systemic Stx 
as a measure of Stx translocation from the intestinal lumen to the systemic circulation in 3-
day-old pigs with and without a host enteric inflammatory response. 
Materials and Methods: 
All procedures were approved by the Iowa State University Animal Care and Use 
Committee. Neonatal (<24 hr's old) Yorkshire/Durok cross piglets (N=35) were obtained 
from a local producer (Laboratory Animal Resources, ISU). The piglets were allowed to 
suckle for up to 12 hours prior to removal from the sow in order to obtain colostral antibodies 
by passive transfer. Pigs were placed in cages that were maintained at 94° F in a climate-
controlled room, and were fed Esbilac (Pet Ag) puppy milk replacer. All pigs were fed 1 mL 
of a solution of 5% lactulose, 1% L-rhamnose, and 1% mannitol as marker sugars to assess 
intestinal permeability (22,40,41). 
Experiment 1, strain 86-24: 
Pigs (N=l 1) were randomly divided into treatment (n= 8) and control (n= 3) groups and were 
allowed to acclimate until three days of age in order allow for gut closure and prevent passive 
transfer of maternal antibodies (42,43). At three days of age, all pigs were infected with 10* 
CPU. of E. co/i 0157:H7 strain 86-24 per os in 20 ml of milk replacer. Starting 8 hr's after 
infection with & co/z strain 86-24, the treatment pigs were dosed with DSS 2.5% as 
previously described (24). Control pigs received a sham treatment of 20 ml milk twice daily. 
All pigs were evaluated as described in "Evaluation" below. 
Experiment 2, strain 86-24 + streptomycin: 
Pigs (N=8) were randomly divided in treatment (n=4) and control (n=4) groups and were 
allowed to acclimate until three days of age in order allow for gut closure and prevent passive 
transfer of maternal antibodies (42,43). The pigs were dosed daily with a solution of non-
metabolized marker sugars (mannitol, L-rhamnose, and lactulose). Five hours after dosing, 
urine was collected via cysto centesis and marker sugar concentration was detected using a 
previously described method (5) (see "Evaluation" below). At three days of age, all pigs 
were dosed with 2.1 x 10^ CPU's of E. co/z 0157:H7 strain 86-24 per os. In order to 
enhance & co/z 0157:H7 colonization and suppress commensal microflora, all pigs were 
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given streptomycin 1 Img/pig per os (21, 33). Half of the pigs (N=4) were dosed with 2.5% 
DSS as previously described (24) starting 8 hours after infection. Control pigs received a 
sham treatment of 20 ml milk twice daily. All pigs were evaluated as described in 
"Evaluation" below. 
Experiment 3, high dose toxin (crude toxin preparation): 
Pigs (N=8) were randomly divided into treatment (n= 4) and control (n=4) groups and were 
allowed to acclimate until three days of age in order allow for gut closure and prevent passive 
transfer of maternal antibodies (42,43). The pigs were dosed daily with a solution of non-
metabolized marker sugars (mannitol, L-rhamnose, and lactulose). Five hours after dosing, 
urine was collected via cysto centesis and marker sugar concentration was detected using a 
previously described method (5) (see "Evaluation" below). Half of the pigs received 2.5% 
DSS as described (24). Control pigs received a sham treatment of 20 ml milk twice daily. 
Starting at 7 days of age, pigs were orally dosed with 5 mL's of crude toxin preparation from 
E. coli strain 86-24 (1 x 107 CD50/ml) two times daily. All pigs were evaluated as described 
in "Evaluation" below. 
Experiment 4, low dose toxin (crude toxin preparation): 
Pigs (N-8) were randomly divided into treatment (n= 4) and control (n=4) groups and were 
allowed to acclimate until three days of age in order allow for gut closure and prevent passive 
transfer of maternal antibodies (42,43). The pigs were dosed daily with a solution of non-
metabolized marker sugars (mannitol, L-rhamnose, and lactulose). Five hours after dosing, 
urine was collected via cysto centesis and marker sugar concentration was detected using a 
previously described method (5) (see "Evaluation" below). The treatment group was further 
subdivided into short term (2 days of treatment, n=2) and long term (4 days of treatment, 
n=2). Starting at 4 days of age, the long term treatment group began receiving DSS 2.5% as 
previously described (24). Two days later (6 days of age) the short term treatment group 
began receiving DSS 2.5% in 20 as previously described (24). Control pigs received sham 
treatments of 20 ml of milk replacer twice daily. DSS administration was stopped on all 
treatment pigs on the evening of day 7 of age. On day 8 of age, all pigs received 1 ml of E. 
co/; strain 86-24 crude toxin preparation (1x10^ cd^/ml) in 20 ml of milk. All pigs were 
evaluated as described in "Evaluation" below. 
Evaluation: 
Food intake, hydration status, activity level, bloody or non-bloody diarrhea, and neurologic 
signs of Stx toxicosis (head pressing, paddling, seizures (3,4)) were recorded for all pigs 
throughout the experiments. Pigs were euthanized on day 11 of age, or when clinical signs 
dictated, for humane reasons, by barbiturate overdose (Beuthanasia) and complete necropsies 
were performed. 
The non-metabolized sugars mannitol, L-rhamnose, and lactulose have been used in pediatric 
medicine as a non-invasive test of intestinal mucosal permeability (5,22,40,41). A mixture 
of 5% lactulose, 1% L-rhamnose, and 1% mannitol in water is given by mouth, and urine is 
collected for 5 hours. The amount and ratio of marker sugars in the urine has been shown to 
give an accurate measurement of mucosal permeability in children (5,22,40,41). A 
modified version of this test was used in pigs. One mL of 5% lactulose, 1% L-rhamnose, and 
100 
1% mannitol was given by mouth to the pigs, and urine was collected 4 hours later by cysto 
centesis, and frozen at -20 C until it could be evaluated for the presence of the marker sugars 
via gas chromatography (5). 
Sections of ileum, cecum, spiral colon, rectum, and brain were collected in 10% neutral 
buffered formalin. Formalin fixed sections were processed and imbedded in paraffin, then 
cut into 5 fim sections and stained with hematoxylin and eosin (H&E), and periodic acid 
Schiff (PAS) stains. H&E stained sections of ileum, cecum, spiral colon, and rectum were 
evaluated histologically and were subjectively scored for degree of inflammation and 
ulceration. 
Inflammatory changes were scored as follows: l=minimal infiltration of inflammatory cells, 
2=mild infiltration of inflammatory cells, 3=moderat:e infiltration of inflammatory cells, 
4-severe infiltration of inflammatory cells. Degree of ulceration was scored as follows: 
0=ulceration of less than 1% of the mucosal surface, l=ulceration of from 1-20% of the 
mucosal surface, ^ulceration of 21-40% of the mucosal surface, 3ulceration of 41-60% of 
the mucosal surface, 4=ulceration of 61-80% of the mucosal surface, 5=ulceration of greater 
than 80% of the mucosal surface. 
PAS stained sections of brain were evaluated for lesions of systemic shiga toxicosis as 
described by Dean-Nystrom and Pohlenz (30). PAS-stained mid-sagittal sections of the right 
half of the cerebellum and brain stem were examined starting at the dorsal midline of the 
brain stem directly below the cerebellar peduncles. 100 random arterioles were assessed for 
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the presence of PAS stained droplets in the space of Virchow surrounding the vessel in these 
areas for each pig. 
H&E stained mid-sagittal sections of the right half of the cerebellum and brain stem were 
examined for the presence of micro-hemorrhages in the cerebellar folia, cerebellar pons, and 
medulla. Each area of the section was considered a significant lesion if there was at least one 
focus of red blood cell leakage into the neuropil surrounding a vessel. Leakage at the 
margins of the tissues or in areas that were obviously damaged during brain removal was not 
included. 
Additional unstained 5 /im sections of ileum, cecum, spiral colon, and rectum were mounted 
to glass slides for immunohistochemical staining of E. co/z 0157:H7 bacteria using an 
OptiMax Plus stainer (Biogenics, San Ramon). Briefly, paraffin embedded sections were cut 
to 5 fi m and adhered to glass slides. 5 fim sections were de-paraffinized in xylene and re-
hydrated through a series of ethanol/water baths. De-paraffinized sections were incubated 
with 3% hydrogen peroxide for 30 minutes to block peroxidase activity. The sections were 
then rinsed in Tris-buffered saline containing 0.05% Tween (TBS-T20) (Sigma, St. Louis, 
MO). Using a wax pen (Pap-pen, Biogenics, San Ramon, CA), two lines were drawn on the 
glass slide, one above and one below the section, to prevent excessive spreading of the 
reagents and tissue drying. The slides were loaded into the slide processor and a previously 
optimized staining protocol was run (2). The slides were incubated with 1:20000 dilution of 
affinity purified goat anti-& co# 0157:H7 polyclonal antibody (Kirkgaard-Perry, 
Gathersburg, MD) 2 times for 45 minutes, and rinsed in TBS-T20. Biotinylated rabbit-anti 
goat antibody was used as a secondary antibody (Kirkgaard-Perry). Signals were developed 
using the Nova Red substrate system (Vector Laboratories, Burlingame, CA). The slides 
were counter-stained with hematoxylin. 
Colonization by A/E bacteria was scored on the immunohistochemically stained sections as 
follows: 0=no attached bacteria visible, 1=<5% of the mucosal surface area of the section 
colonized, 2=5-10% of the mucosal surface of the section colonized, 3=10-25% of the 
mucosal surface of the section colonized, 4=>25% of the mucosal surface of the section 
colonized. 
Statistical significance of parametric data was determined by single factor analysis of 
variance (ANOVA) and statistical significance of non-parametric data was determined by the 
Wilcox test using the statistical software analysis package JMP 5.0.1a (SAS Institute). 
Results: 
Clinical Signs: 
In all 4 studies, pigs that received DSS developed bloody diarrhea while pigs that did not 
receive DSS did not develop bloody diarrhea. Likewise, dehydration and lethargy were seen 
in DSS treated pigs, but not in those that did not receive DSS. This finding was consistent 
with our previous findings that DSS induces bloody diarrhea and dehydration in pigs (24). 
Clinical signs of systemic Stx intoxication (head pressing, seizures, and paddling) were seen 
in the high dose Stx experiment (experiment 3), but were not seen in the 86-24 colonization 
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experiments (experiments 1 and 2) or the low dose Stx experiment (experiment 4). In the hi 
dose toxin experiment (experiment 3) clinical signs of Stx toxicosis were seen in both pigs 
that received DSS and those that did not receive DSS. 
Marker sugars: 
The concentration of marker sugars in the urine of pigs was below the level of quantification 
in the majority (49/52) of samples tested. However, trace amounts (detectable, but below the 
threshold level of quantification by GC (50 or 100 ppm depending on the sugar)) of one or 
more of the sugars were detected in 45 out of 52 samples. Using the presence of trace 
amounts of the sugars as a non-parametric measurement of marker sugar absorption, there 
was a significant difference in the absorption of mannitol (p=0.05) (Figure 1) and lactulose 
(p=0.05) (Figure 2), but not L-rhamnose in animals treated with DSS versus those not treated 
with DSS. Interestingly, mannitol was absorbed to a greater extent in animals that did not 
receive DSS versus those that did, while Lactulose was absorbed to a greater extent in 
animals that did receive DSS versus those that did not. Additionally, significantly greater 
absorption of mannitol (p=0.03), L-rhamnose (p=0.04), and lactulose (p=0.04) was seen in 
the high dose toxin group (DSS 18) than in the low dose toxin group (DSS 21) and the live 
bacteria group (DSS 17) (Figure 3) (Figure 4) (Figure 5). 
Histopathology: 
Examination by light microscopy showed that DSS caused a significant increase in both 
inflammation (pcO.OOOl) and ulceration (p<0.0001) in the cecum, spiral colon, and rectum of 
pigs that received DSS treatment vs. pigs that did not receive DSS treatment (Figure 6) 
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(Figure 7). Pigs treated with DSS had severe suppurative inflammation in the cecum, spiral 
colon, and rectum with numerous neutrophils in the intestinal lumen, within and between 
intestinal epithelial cells, and in the lamina propria, tunica submucosa, and in some cases 
within the tunica muscularis (Figure 8). In addition, DSS treated pigs had large areas of 
ulceration that covered anywhere from less than 5% to 100% of the surface area of the 
section (Figure 9). In general, ulceration was most severe in the spiral colon of DSS treated 
pigs, with the cecum and rectum usually being less severely affected. Non-DSS treated pigs 
had minimal to mild inflammatory infiltrates in the cecum, spiral colon, and rectum that were 
similar in severity to those seen in age matched controls from previous studies. 
DSS caused a significant (p=0.0055) decrease in the extent of E. co/i 0157:H7 A/E lesions in 
the large intestine (Figure 10). 
Extraintestinal lesions: 
Stx is known to cause microvascular hemorrhages in the medulla, cerebellar pons, and 
cerebellar folia (Figure 11) and leakage of PAS positive material (Figure 12) from vessels 
(30,39). PAS stained droplets were present in all pigs and were similar in DSS-treated and 
sham-treated pigs. Likewise, there was no significant difference in the presence of 
microvascular hemorrhages in either the cerebellar folia, the cerebellar pons, or the medulla 
between DSS-treated and sham-treated pigs in any of the experiments (Figure 13). 
The oral toxin groups (experiments 3 & 4) had a significantly higher rate of microvascular 
hemorrhages (p=0.0012) compared to the groups that were inoculated with & co/i strain 86-
24 (experiments 1 & 2) (Figure 14). However, within these groups, treatment with DSS 
made no significant difference on the rate of cerebellar micro-hemorrhages. 
Discussion: 
To the best of our knowledge, this is the first report of clinical signs and histologic lesions 
associated with oral administration of Stx 2 in pigs. The results of these studies were 
consistent with our earlier findings in that DSS induced significant increases in both 
inflammation and ulceration in the large intestine of pigs (24). However, this increase in 
inflammation and ulceration appeared to have mixed effects on the absorption of the marker 
sugars mannitol, lactulose, and L-rhamnose, and did not appear to increase the translocation 
of Stx from the intestinal lumen to the systemic circulation, based upon measurement of 
vascular leakage as determined by PAS staining in the medulla, and microvascular 
hemorrhages in the cerebellar folia, pons, and underlying medulla. 
The finding that inflammation did not enhance Stx translocation is interesting because ;'n 
vffro studies have shown that inflammatory changes, particularly neutrophil transmigration, 
increase the translocation of Stx across polarized intestinal epithelial cells in a manner that is 
dependent on the number of neutrophils that transmigrate across the epithelial cells(12,14, 
26,27,29). Additionally, Stx has been shown to bind to neutrophils in humans (36-38) and 
in pigs (personal communication, Shannon Jones Hostetter), and neutrophilia in humans is 
associated with a higher chance of developing HUS in EHEC infections. 
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It is possible that DSS, being a sulfonated carbohydrate chain, acts as a sink to bind Stx in the 
intestinal lumen like several other compounds are known to do (28, 32). Thus, it is possible 
that, although DSS was only given twice daily to treatment pigs, there was enough DSS in 
the lumen of the intestine to bind Stx, and therefore less Stx was available to cross from the 
intestinal lumen to the systemic circulation. However, in experiment 4, pigs were treated 
with DSS and then the DSS was withdrawn for 24 hours in order to allow it to clear the 
intestinal lumen prior to dosing with oral Stx. Even with this change, no difference between 
pigs with inflammation versus those without inflammation was seen, even when DSS was 
cleared from the intestinal tract. 
In the bacterial colonization studies (experiments 1 and 2), it is possible that the decreased 
total enterocyte surface area associated with villous contraction and ulceration of the mucosal 
surface resulted in decreased bacterial growth/colonization and/or decreased Stx production, 
which could have obscured changes in Stx absorption. Additionally, DSS may have had 
direct inhibitory effects on the growth of & co/z 0157:H7 strain 86-24, or may have 
suppressed Stx production by the bacteria. A possible complicating factor in the crude toxin 
preparation studies (experiments 3 and 4) is absorption of Stx in the small intestine before 
reaching the area affected by DSS. Additional studies to address these concerns are planned. 
It is possible that inflammation and ulceration do affect the translocation of Stx from the 
intestinal lumen to the systemic circulation, but measurements of Stx translocation were not 
sensitive enough to identify the change. Stx translocation could not be detected via the Vero 
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cell assay, even in pigs that had extra-intestinal histopathologic lesions of Stx (cerebellar 
microhemorrhages). It could be that Stx is only very transiently present in the systemic 
circulation, making it difficult to detect, or that Stx is bound to a carrier substance in the 
systemic circulation, such as the neutrophil, and is thus not available to interact with Vero 
cells in the assay. Apoptosis is another measure of systemic Stx damage and Stx is known to 
cause apoptosis in endothelial cells in the kidney and brain. However, TUNEL staining 
procedures were unsuccessful in pig tissues in our lab and were not uniformly specific for 
apoptosis. Some of the caspase assays may be useful for detecting apoptosis in the pig, and 
may provide a more sensitive measure of systemic Stx damage. 
Alternatively, it may be that our measurement of PAS and hemorrhagic lesions are 
adequately sensitive and that inflammation and ulceration does not influence Stx 
translocation in EHEC infections. The increased risk of HUS in individuals with elevated 
neutrophil counts and inflammatory mediators may simply indicate that the EHEC infection, 
rather than the host response, is more severe. It has been shown that small amounts of Stx II 
translocate across polarized intestinal epithelium. Since Stx is a very potent toxin, this small 
amount of physiologic translocation may be sufficient to induce HUS and other systemic 
effects of Stx. However, if this is the case, the discordance between disease outcome and 
fecal Stx remains puzzling (1). 
Gas chromatography detection of marker sugars demonstrated that there are differences in 
marker sugar absorption between pigs that received DSS versus those that did not. However, 
a higher level of sensitivity of detection and quantification may more precisely differentiate 
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mucosal changes in permeability. The GC method is used humans, but pigs may have subtle 
differences in excretion. Also initial concentrations of marker sugars administered could be 
different, or the timing between dosing with the sugars and collecting urine could be different 
could be different in humans versus pigs. In humans, total urine output is typically collected, 
but this is not possible in neonatal pigs. More sensitive means of detection, such as high 
performance liquid chromatography, or alteration of the timing between dosing and urine 
collection and the initial dosing volume may prove beneficial to adapting the method of 
measurement in pigs. 
The decreased absorption of mannitol in DSS treated groups versus sham treatment groups is 
surprising, since DSS increased lactulose absorption and DSS treatment clearly caused 
mucosal lesions, but may be due to interference or interaction of DSS with mannitol. 
Alternatively, since mannitol is used as a marker of transcellular permeability, the decrease 
in mucosal cells present may have been responsible for the decreased mannitol absorption in 
DSS treatment groups versus sham treatment groups. 
Clearly, much work needs to be done in order to completely understand the mechanism of 
Stx translocation between the intestinal lumen and the systemic circulation. 
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Figure 1. Mosaic plot of mannitol detection by gas chromatography in the urine of pigs treated with 
dextran sulfate sodium (DSS) versus pigs not treated with DSS. The colors red, green, and blue represent 
no detectable level of mannitol, trace levels of mannitol (<50 ppm) and measurable amounts of mannitol 
(>50 ppm) respectively. Mannitol detection in the urine is significantly greater (p=0.05) in pigs that were 
not treated with DSS (DSS-) versus pigs treated with DSS (DSS +). 
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Figure 2. Mosaic plot of lactulose detection by gas chromatography in the urine of pigs treated with 
dextran sulfate sodium (DSS) versus pigs not treated with DSS. Lactulose detection in the urine is 
significantly greater (p=0.05) in pigs that were treated with DSS (DSS+) versus pigs that were not treated 
with DSS (DSS -). The colors red, green, and blue represent no detectable level of lactulose, trace levels 
of lactulose (<100 ppm) and measurable amounts of lactulose (>100 ppm) respectively. 
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Figure 3. Mosaic plot of mannitol detection by gas chromatography in the urine of pigs. DSS 17 pigs 
(n=4() were dosed with & co# 0157:H7 strain 86-24 and streptomycin, DSS 18 pigs (n-8) were dosed with 
5 mL of & coW 0157:H7 crude toxin preparation, l(f CD*/mL daily (High dose Shiga toxin), and DSS 21 
pigs were dose with 1 mL of E. coli 0157:H7 crude toxin preparation, 107 CD^/mL once (Low dose Shiga 
toxin). Mannitol dectection was significantly higher (p=0.02) in DSS 18 pigs versus DSS 17 and DSS 21. 
There was no significant difference in mannitol detection in DSS 17 versus DSS 21 pigs. The colors red, 
green, and blue represent no detectable level of mannitol, trace levels of mannitol (<50 ppm) and 
measurable amounts of mannitol (>50 ppm) respectively. 
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Figure 4. Mosaic plot of L-rhamnose detection by gas chromatography in the urine of pigs. DSS 17 pigs 
(n=8) were dosed with E. coli Q157:H7 strain 86-24 and streptomycin, DSS 18 pigs (n=8) were dosed with 
5 mL of & co# Q157:H7 crude toxin preparation, 10  ^CD*VmL daily (High dose Shiga toxin), and DSS 21 
pigs were dose with 1 mL off! co& 0157:H7 crude toxin preparation, 10  ^CD™/mL once (Low dose Shiga 
toxin). L-rhamnose was significantly higher (p=0.04) in DSS 18 pigs versus DSS 17 and DSS 21. There 
was no significant difference in L-rhamnose detection in DSS 17 versus DSS 21 pigs. The colors red, 
green, and blue represent no detectable level of L-rhamnose, trace levels of L-rhamnose (<50 ppm) and 
measurable amounts of L-rhamnose (>50 ppm) respectively. 
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Figure 5. Mosaic plot of lactulose detection by gas chromatography in the urine of pigs. DSS 17 pigs 
(n=8) were dosed with & co& 0157:H7 strain 86-24 and streptomycin, DSS 18 pigs (n=8) were dosed with 
5 mL of E. coli 0157:117 crude toxin preparation, 107 CDS0/mL daily (High dose Shiga toxin), and DSS 21 
pigs were dose with 1 mL of E. coli 0157:H7 crude toxin preparation, 107 CD^/mL once (Low dose Shiga 
toxin). Lactulose was significantly higher (p=0.04) in DSS 18 pigs versus DSS 17 and DSS 21. There was 
no significant difference in L-rhamnose detection in DSS 17 versus DSS 21 pigs. The colors red, green, 
and blue represent no detectable level of lactulose, trace levels of lactulose (<100 ppm) and measurable 
amounts of lactulose (>100 ppm) respectively. 
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Figure 6. Mosaic plot of inflammation In pigs treated with dextran sulfate sodium (DSS) versus pigs not 
treated with DSS (none). The color: represent the different inflammation scores (1-4) assigned to cecal, 
spiral colon, and rectal histologic sections (combined) (see Materials and Methods). There is significantly 
greater inflammation (p<0.0001) in DSS treated pigs versus pigs not treated with DSS. 
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Figure 7. Mosaic plot of ulceration in pigs treated with dextran sulfate sodium (DSS) versus pigs not 
treated with DSS (none). The colors represent the different ulceration scores (0-5) assigned to cecal, 
spiral colon, and rectal histologic sections (combined) (see Materials and Methods). There is significantly 
greater ulceration (p<0.0001) in DSS treated pigs versus pigs not treated with DSS. 
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Figure 8. Photomicrograph (40 x) of the spiral colon demonstrating the typical inflammatory changes 
seen in the cecum, spiral colon, and rectum of pigs treated with dextran sulfate sodium (DSS). Note the 
crypt abscesses (small arrows) and areas of epithelial restitution (large arrow). Bar=50 micrometers. 
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Figure 9. Photomicrograph (10 x) of the spiral colon demonstrating the typical ulcerative changes seen in 
the cecum, spiral colon, and rectum of pigs treated with dextran sulfate sodium (DSS). The arrows 
indicate a large area of ulceration, and smaller area of ulceration. Bar=200 micrometers. 
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Figure 10. Mosaic plot of & 0157:H7 colonization scores in the large intestine (combined) of pigs 
treated with dextran sulfate sodium (DSS) versus those not treated with DSS (none). There was 
significantly less colonization (p=0.006), based upon the presence of attaching and effacing lesions, in pigs 
treated with DSS versus those not treated with DSS. The colors represent the different colonization 
scores (0-4) assigned to sections of cecum, spiral colon, and rectum (see Materials and Methods). 
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Figure 11. Microvascular hemorrhages in the cerebellar folium of a pig treated with Shiga toxin crude 
toxin preparation 5 days after onset of treatment. Arrows denote foci of microvascular hemorrhage. 
H&E stain. Bar=200 micrometers. 
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Figure 12. PAS stained droplets surrounding an arteriole in the medulla oblongata of a pig treated with 
Shiga toxin crude toxin preparation taken 5 days after onset of treatment. Arrows denote PAS positive 
droplets along the neuropil surrounding the vessel. These droplets are due to vascular leakage. PAS 
stain. Bar=50 micrometers. 
126 
none 
Figure 13. Mosaic plot showing the presence of hemorrhage in the cerebellar folia, pons, and medullar 
oblongata of pigs treated with dextran sulfate sodium (DSS) and those not treated with DSS (none). AH 
pigs also received either E. coli 0157:H7 bacterial inoculum or E. coli 0157:H7 crude toxin preparation, 
There is no statistical difference between the groups, indicating the treatment with DSS did not have an 
effect on the presence of Shiga toxin induced microvascular hemorrhages in the pigs. 
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Figure 14. Mosaic plot of the presence of microvascular hemorrhages in the cerebellar folia, pons, and 
medulla oblongata in pigs that received either E. coli 0157:H7 bacterial inoculum (86-24) or E. coli 
0157:H7 crude toxin preparation (tox). The pigs that received crude toxin preparation had a 
significantly higher (p=0.0012) presence of microvascular hemorrhages compared to pigs that received 
bacterial inoculum. 
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General Conclusions 
& coA 0157:H7 is an enterohemorrhagic & co/i that is responsible for morbidity and 
mortality in children and adults throughout the industrialized world. Hemolytic uremic 
syndrome induced by E. co# 0157:H7 is the leading cause of acute renal failure in children 
in the United States, and is a cause of chronic renal sequela in many of the children affected. 
Much has been learned about the pathogenesis of EHEC colonization, bacteria-host 
interactions, and HUS development. One of the steps of the pathogenesis of EHEC infection 
that remains undefined is Shiga toxin (Stx) translocation from the intestinal lumen to the 
systemic circulation. Several m vzfro studies have shown that Shiga toxin 2 (Stx 2) 
translocation is enhanced by neutrophil transmigration across polarized intestinal epithelial 
cells. Other studies have shown that neutrophils and their products induce Stx production, 
and bind Stx in humans. It seems likely that in vivo translocation of Stx would be enhanced 
by the host inflammatory response to EHEC. 
The purpose of the papers presented in this thesis was to develop an m vzvo model of EHEC 
infection where host inflammation could be controlled so that Stx translocation in the 
presence and in the absence of the host inflammatory response could be assessed. 
The first experiment demonstrated that conventional pigs infected with E. co/f 0157:H7 at 
three days of age, after physiologic gut closure, were colonized by E. co/f 0157:H7 and 
developed classic attaching and effacing lesions of & coZz 0157:H7, but lacked both a 
histologically detectable host inflammatory response as compared to age matched controls, 
and clinical signs of systemic Stx toxicosis. This showed that the 3-day-old pig could be 
used as a model of EHEC infection. 
The second experiment demonstrated that dextran sulfate sodium (DSS), which has been 
used in the guinea pig, mouse, and rat to induce colonic inflammation, reliably induced 
inflammation of the cecum, spiral colon, and rectum of the neonatal pig. The significance of 
the this experiment was that it provided a method of inducing inflammation and ulceration at 
the sites of EHEC colonization in conventional 3-day-old pigs. 
The third experiment compared clinical outcome and histologic lesions of systemic Stx 
intoxication in pigs that had an intense inflammatory response in the large intestine versus 
pigs that had a minimal or no inflammatory response in the large intestine. Clinical and 
histologic measurements were used to determine whether Stx had translocated into the 
systemic circulation . We were unable to detect Stx in the blood of any pigs, even those that 
had systemic lesions of Shiga toxicosis using the Vero cell assay. Likewise, TUNEL staining 
did not work reliably in our lab on pig tissues. The lesions that we chose to examine have 
been described in the scientific literature in association with Stx intoxication in pigs [1-4], 
and since the most important measurement in real world disease is the outcome, systemic 
lesions of Stx are arguably the ultimate measure of success or failure of a treatment. 
Based upon the model that we developed to test our hypothesis, the host inflammatory 
reaction to DSS does not enhance Stx absorption, as measured by the presence of systemic 
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lesions of Stx toxicosis, in the 3-day-old pig. However, it is possible that DSS directly or 
indirectly affected the growth/colonization and/or Stx production of E. co/z 0157:H7 strain 
86-24 in these experiments. In addition, it is possible that less severe inflammation and/or 
ulceration may have a different effect on Stx translocation. 
Additional m vzfro tests to determine the effects of DSS on growth and toxin production of E. 
coli 0157:H7 as well as additional z/z vzvo tests involving less severe inflammatory changes 
will be helpful to further define the mechanism of Stx translocation from the intestinal lumen 
to the systemic circulation. 
"It is a sad thing, indeed, to see a beautiful hypothesis crushed by cold, hard, observations." -
original author unknown to me, but often repeated by my father. 
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